

in which

W is $R^1-A-C(R^{13}) < :$

Y is a carbonyl:

Z is $N(R^0)$;

A is a bivalent radical from the group consisting of (C_1-C_6) -alkylene, (C_2-C_7) -cycloalkylene, phenylene, phenylene- (C_1-C_6) -alkyl, (C_1-C_6) -alkylenephenyl, phenylene- (C_2-C_6) -alkenyl or a bivalent radical of a 5- or 6-inembered saturated or unsaturated ring which can contain 1 or 2 nitrogen atoms and can be mono- or disubstituted by (C_1-C_6) -alkyl or doubly bonded oxygen or sulfur;

B is a bivalent radical from the group consisting of (C_1-C_6) -alkylene, (C_2-C_6) -alkenylene, phenylene, phenylene- (C_1-C_3) -alkyl, (C_1-C_4) -alkylenephenyl, where the bivalent (C_1-C_6) -alkylene radical can be unsubstituted or substituted by a radical from the group consisting of (C_1-C_8) -alkyl, (C_2-C_8) -alkenyl, (C_3-C_8) -alkynyl, (C_3-C_{10}) -cycloalkyl, (C_3-C_{10}) -cycloalkyl- (C_1-C_6) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl and heteroaryl- (C_1-C_6) -alkyl optionally substituted in the heteroaryl radical;

D is $C(R^2)(R^3)$, $N(R^3)$ or $CH = C(R^3)$;

E is R¹⁰CO;

R is hydrogen, (C_1-C_2) -alkyl, (C_3-C_2) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl- (C_1-C_2) -alkyl optionally substituted in the aryl radical:

R⁰ is hydrogen, (C_1-C_2) -alkyl, (C_1-C_{12}) -cycloalkyl, (C_3-C_{12}) -cycloalkyl, (C_1-C_2) -alkyl, (C_2-C_{12}) -bicycloalkyl, (C_2-C_{12}) -tricycloalkyl, (C_2-C_{12}) -tricycloalkyl, (C_2-C_{12}) -tricycloalkyl, (C_2-C_{12}) -aryl, (C_2-C_{12}) -aryl, (C_2-C_{12}) -aryl- (C_1-C_2) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl, heteroaryl- (C_1-C_2) -aryl- (C_1-C_2) -ar





 $\begin{array}{c} \underline{C_{g}}\text{-alkyl optionally substituted in the heteroaryl radical, CHO, } (\underline{C_{1}}\text{-}\underline{C_{g}}\text{-alkyl-CO}, } (\underline{C_{3}}\text{-}\underline{C_{12}}\text{)-}\\ \underline{cycloalkyl-CO, } (\underline{C_{2}}\text{-}\underline{C_{12}}\text{)-cycloalkyl-}(\underline{C_{1}}\text{-}\underline{C_{g}}\text{)-alkyl-CO}, } (\underline{C_{6}}\text{-}\underline{C_{12}}\text{)-bicycloalkyl-CO}, } (\underline{C_{6}}\text{-}\underline{C_{12}}\text{)-bicycloalkyl-CO}, } (\underline{C_{6}}\text{-}\underline{C_{12}}\text{)-tricycloalkyl-CO}, } (\underline{C_{6}}\text{-}\underline{C_{12}}\text{)-tricycloalkyl-CO}, } (\underline{C_{6}}\text{-}\underline{C_{12}}\text{)-tricycloalkyl-CO}, } (\underline{C_{6}}\text{-}\underline{C_{12}}\text{)-tricycloalkyl-CO}, } (\underline{C_{6}}\text{-}\underline{C_{12}}\text{)-tricycloalkyl-CO}, } (\underline{C_{6}}\text{-}\underline{C_{12}}\text{)-tricycloalkyl-CO}, } (\underline{C_{1}}\text{-}\underline{C_{2}}\text{)-alkyl-CO}, } (\underline{C_{1}}\text{-}\underline{C_{2}}\text{)-alkyl-S(O)}_{\underline{n}}, } (\underline{C_{1}}\text{-}\underline{C_{2}}\text{)-alkyl-S(O)}_{\underline{n}}, } (\underline{C_{1}}\text{-}\underline{C_{2}}\text{)-alkyl-S(O)}_{\underline{n}}, } (\underline{C_{1}}\text{-}\underline{C_{2}}\text{)-alkyl-S(O)}_{\underline{n}}, } (\underline{C_{2}}\text{-}\underline{C_{12}}\text{)-bicycloalkyl-} (\underline{C_{1}}\text{-}\underline{C_{2}}\text{)-alkyl-S(O)}_{\underline{n}}, } (\underline{C_{2}}\text{-}\underline{C_{12}}\text{)-aryl-stricycloalkyl-S(O)}_{\underline{n}}, } (\underline{C_{2}}\text{-}\underline{C_{2}}\text{)-alkyl-S(O)}_{\underline{n}}, } (\underline{C_{2}}\text{-}\underline{C_{2}}\text{)-aryl-stricycloalkyl-S(O)}_{\underline{n}}, } (\underline{C_{2}}\text{-}\underline{C_{2}}\text{)-aryl-stricycloalkyl-S(O)}_{\underline{n}}, } (\underline{C_{2}}\text{-}\underline{C_{2}}\text{)-aryl-stricycloalkyl-stricycloalkyl-stricycloalkyl-stricycloalkyl-stricycloalkyl-stricycloalkyl-st$

- R^1 is X-NH-C(=NH)-(CH₂)_p or Σ^1 -NH-(CH₂)_p, where p is 0, 1, 2 or 3;
- X is hydrogen, (C_1-C_6) -alkyl, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_6) -alkoxycarbonyl, optionally substituted (C_6-C_{14}) -arylcarbonyl, optionally substituted (C_6-C_{14}) -arylcarbonyl, optionally substituted (C_6-C_{14}) -aryloxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl which can also be substituted in the aryl radical, $(R^8O)_2P(O)$, cyano, hydroxyl, (C_1-C_6) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxy which can also be substituted in the aryl radical, or amino;
- X^1 has one of the meanings of X or is R'-NH-C(=N-R''), where R' and R'' independently of one another have the meanings of X:
- R² is hydrogen, (C_1-C_2) -alkyl, optionally substituted (C_2-C_{14}) -aryl, (C_2-C_{14}) -aryl- (C_1-C_2) -alkyl optionally substituted in the aryl radical or (C_3-C_2) -cycloalkyl;
- R³ is hydrogen, (C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical, (C₂-C₈)-cycloalkyl, (C₂-C₈)-alkenyl, (C₂-C₈)-alkenyl, (C₂-C₈)-alkynyl, (C₂-C₈)-alkynylcarbonyl, pyridyl, R¹¹NH, R⁴CO, COOR⁴, CON(CH₃)R¹⁴, CON)HR¹⁴, CSNHR¹⁴, COOR¹⁵, CON(CH₃)R¹⁵ or CONHR¹⁵;
- R⁴ is hydrogen or (C₁-C₂₈)-alkyl v/hich can optionally be mono- or polysubstituted by identical or different radicals R⁴; R⁴ is hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or di
 ((C₁-C₁₈)-alkyl)aminocarbonyl, amino-(C₂-C₁₈)-alkylaminocarbonyl, amino-(C₁-C₃)-



alkylphenyl- (C_1-C_2) -alkylaminocarbonyl, (C_1-C_{18}) -alkylcarbonylamino- (C_1-C_3) -alkylphenyl- (C_1-C_3) -alkylaminocarbonyl, (C_1-C_{18}) -alkylcarbonylamino- (C_2-C_{18}) -alkylaminocarbonyl, (C_2-C_{18}) -alkylaminocarbonyl, (C_3-C_{18}) -alkoxycarbonyl which can also be substituted in the aryl radical, amino, mercapto, (C_1-C_{18}) -alkoxycarbonyl, optionally substituted (C_3-C_8) -cycloalkyl, halogen, nitro, trifluoromethyl or the radical R^5 ;

R⁵ is optionally substituted (C₅-C₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical, a mono- or bicyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated or completely hydrogenated and which can contain one, two or three identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur, a radical R⁵ or a radical R⁶CO-, where the aryl radical and, independently thereof, the heterocyclic radical can be mono- or polysubstituted by identical or different radicals from the group consisting of (C₁-C₁₈)-alkyl, (C₁-C₁₈)-alkoxy, halogen, nitro, amino and trifluoromethyl;

R⁶ is R⁷R⁸N, R⁷O or R⁷S or an antino acid side chain, a natural or unnatural amino acid, imino acid, optionally N-(C₁-C₂)-alkylated or N-((C₆-C₁₄)-aryl-(C₁-C₂)-alkylated) azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to -NH-CH₂-, and their esters and amides, where hydrogen or hydroxymethyl can optionally stand in place of free functional groups and/or where free functional groups can be protected by protective groups customary in peptide chemistry;

R⁷ is hydrogen, (C₁-C₁₈)-alkyl, (C₁-C₁₄)-aryl-(C₁-C₂)-alkyl, (C₁-C₁₈)-alkylcarbonyl, (C₁-C₁₈)-alkylcarbonyl, (C₁-C₁₄)-aryl-aryl-(C₁-C₂)-alkylcarbonyl or (C₂-C₁₄)-aryl-(C₁-C₂)-alkyloxycarbonyl, where the alkyl groups can optionally be substituted by an amino group and/or where the aryl radicals can be mono- or polysubstituted, preferably monosubstituted, by identical or different radicals from the group consisting of (C₁-C₂)-alkyl, (C₁-C₂)-alkoxy, halogen, nitro, amino and trifluoromethyl, or is a natural or unnatural amino acid, imino acid, optionally N-(C₁-C₂)-alkylated or N-((C₂-C₁₄)-aryl-(C₁-C₂)-alkylated) azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to -NH-CH₂-;

R⁸ is hydrogen, (C_1-C_{18}) -alkyl, or tionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl which can also be substituted in the aryl radical;



- R⁹ is hydrogen, aminocarbonyl, (C₁-C₁₈)-alkylaminocarbonyl, (C₂-C₃)-cycloalkylaminocarbonyl, optionally substituted (C₆-C₁₄)-arylaminocarbonyl, (C₁-C₁₈)-alkyl, optionally substituted (C₆-C₁₄)-arylor (C₂-C₈)-cycloalkyl;
- R¹⁰ is hydroxyl, (C_1-C_{18}) -alkoxy. (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;
- R¹¹ is hydrogen, (C_1-C_{18}) -alkyl, (C_1-C_{18}) -alkyl optionally substituted (C_5-C_{14}) -aryl- (C_1-C_{18}) -alkyl- (C_5-C_{14}) -aryl- (C_5-C_{14}) -aryl
- R¹² is hydrogen, (C_1-C_{18}) -alkyl, (C_2-C_{18}) -alkenyl, (C_2-C_{18}) -alkynyl, optionally substituted (C_6-C_{14}) -aryl, (C_1-C_{18}) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_{18}) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;
- R¹³ is hydrogen, (C_1-C_6) -alkyl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or (C_3-C_8) -cycloalkyl.
- identical or different radicals from the group consisting of hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or di- (C₁-C₁₈)-alkyl)-aminocarbonyl, amino-(C₂-C₁₈)-alkylaminocarbonyl, amino-(C₁-C₁)-alkylphenyl-(C₁-C₂)-alkylaminocarbonyl, (C₁-C₁₈)-alkylcarbonylamino-(C₁-C₂)-alkylphenyl-(C₁-C₂)-alkylaminocarbonyl, (C₁-C₁₈)-alkylcarbonylamino-(C₂-C₁₈)-alkylaminocarbonyl, (C₂-C₁₈)-alkylaminocarbonyl which can also be substituted in the aryl radical, amino, mercapto, (C₁-C₁₈)-alkoxycarbonyl which can also be substituted in the aryl radical, amino, mercapto, (C₁-C₁₈)-alkoxy, (C₁-C₁₈)-alkoxycarbonyl, optionally substituted (C₂-C₂)-cycloalkyl, HOS(O)₂-(C₁-C₂)-alkyl, R⁹NHS(O)₂-(C₁-C₂)-alkyl, (R¹⁰O)₂P(O)-(C₁-C₂)-alkyl, tetrazolyl-(C₁-C₂)-alkyl, halogen, nitro, trifluoromethyl and R⁵;

 R^{15} is R^{16} -(C_1 - C_6)-alkyl or R^{16} :

R¹⁶ is a 6- to 24-membered bicyc ic or tricyclic radical which is saturated or partially unsaturated and which can also contain one to four identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur and which can also be substituted by



one or more identical or different substituents from the group consisting of (C1-C4)-alkyl and oxo;

b, c, and d are 1;

e is 0, 1, 2, 3, 4, 5 or 6:

<u>f</u> is 0;

g is 0, 1, 2, 3, 4, 5 or 6;

h is 0, 1, 2, 3, 4, 5 or 6;

in all their stereoisomeric forms and mixtures thereof in any ratio, and of their physiologically tolerable salts.

22. (amended) A method for antagonizing VLA-4 comprising administering to a subject in need thereof an effective amount of [the preparation as claimed in claim 1] a preparation comprising an effective amount of at least one compound of the formula I:

in which

W is $R^{1}-A-C(R^{13}) < :$

Y is a carbonyl:

Z is $N(R^0)$:

- A is a bivalent radical from the group consisting of (C_1-C_6) -alkylene, (C_3-C_1) -cycloalkylene, phenylene, phenylene- (C_1-C_2) -alkyl, (C_1-C_2) -alkylenephenyl, phenylene- (C_2-C_2) -alkenyl or a bivalent radical of a 5- or 6-membered saturated or unsaturated ring which can contain 1 or 2 nitrogen atoms and can be mono- or disubstituted by (C1-C2)-alkyl or doubly bonded oxygen or sulfur;
- B is a bivalent radical from the group consisting of (C_1-C_6) -alkylene, (C_2-C_6) -alkenylene, phenylene, phenylene- (C_1-C_2) -alkyl, (C_1-C_3) -alkylenephenyl, where the bivalent (C_1-C_2) alkylene radical can be unsubstituted or substituted by a radical from the group consisting



of (C_1-C_2) -alkyl, (C_2-C_3) -alkeryl, (C_2-C_3) -alkynyl, (C_3-C_{10}) -cycloalkyl, (C_3-C_{10}) -cycloalkyl- (C_1-C_2) -alkyl, optionally substituted (C_2-C_{14}) -aryl, (C_2-C_{14}) -aryl- (C_1-C_2) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl and heteroaryl- (C_1-C_2) -alkyl optionally substituted in the heteroaryl radical;


<u>D</u> is $C(R^2)(R^3)$, $N(R^3)$ or $CH = C(R^3)$;

E is R¹⁰CO:

 R^0 is hydrogen, (C_1-C_2) -alkyl, (C_1-C_{12}) -cycloalkyl, (C_3-C_{12}) -cycloalkyl- (C_1-C_2) -alkyl, (C_6-C_{12}) bicycloalkyl, (C_6-C_{12}) -bicycloalkyl- (C_1-C_8) -alkyl, (C_6-C_{12}) -tricycloalkyl, (C_6-C_{12}) tricycloalkyl-(C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical optionally substituted heteroaryl, heteroaryl-(C₁- C_8)-alkyl optionally substituted in the heteroaryl radical, CHO, (C_1-C_8) -alkyl-CO, (C_2-C_{12}) cycloalkyl-CO, (C_3-C_{12}) -cycloalkyl-CO, (C_6-C_{12}) -bicycloalkyl-CO, (C_6-C_{12}) bicycloalkyl-(C₁-C₈)-alkyl-CO. (C₆-C₁₂)-tricycloalkyl-CO. (C₆-C₁₂)-tricycloalkyl- (C_1-C_8) -alkyl-CO, optionally substituted (C_6-C_{14}) -aryl-CO, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl-CO optionally substituted in the aryl radical, optionally substituted heteroaryl-CO, heteroaryl-(C₁-C₈)-alkyl-CO optionally substituted in the heteroaryl radical, (C₁-C₈)-alkyl-S(O)₁, (C_3-C_{12}) -cycloalkyl- $S(O)_n$, (C_3-C_{12}) -cycloalkyl- (C_1-C_2) -alkyl- $S(O)_n$, (C_6-C_{12}) -bicycloalkyl- $S(O)_{n}$, (C_6-C_{12}) -bicycloalkyl- (C_1-C_8) -alkyl- $S(O)_{n}$, (C_6-C_{12}) -tricycloalkyl- $S(O)_{n}$, (C_6-C_{12}) - $\underline{\text{tricycloalkyl-}(C_1-C_8)-\text{alkyl-S(C)}}_{\underline{0}}, \underline{\text{optionally substituted }}(C_{\underline{6}}-C_{\underline{14}})-\underline{\text{aryl-S(O)}}_{\underline{0}}, \underline{(C_{\underline{6}}-C_{\underline{14}})-\underline{\text{aryl-S(O)}}_{\underline{0}}}$ (C₁-C₂)-alkyl-S(O)_n optionally substituted in the aryl radical, optionally substituted heteroaryl-S(O), or heteroaryl-(C₁-C₈)-alkyl-S(O), optionally substituted in the heteroaryl radical, where n is 1 or 2;

 R^1 is X-NH-C(=NH)-(CH₂)_p of Σ^1 -NH-(CH₂)_p, where p is 0, 1, 2 or 3;

X is hydrogen, (C_1-C_6) -alkyl, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_6) -alkoxycarbonyl, optionally substituted (C_6-C_{14}) -arylcarbonyl, optionally substituted (C_6-C_{14}) -aryloxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl which can also be substituted in the aryl radical, $(R^8O)_2P(O)$, cyano, hydroxyl, (C_1-C_6) -



10/14/99 THU 22:31 FAX 6391

alkoxy, (C₆-C₁₄)-aryl-(C₁-C₆)-alkoxy which can also be substituted in the aryl radical, or amino;

- X^1 has one of the meanings of X or is R'-NH-C(\Rightarrow N-R''), where R' and R'' independently of one another have the meanings of X;
- R² is hydrogen, (C_1-C_2) -alkyl, op ionally substituted (C_2-C_{14}) -aryl, (C_5-C_{14}) -aryl- (C_1-C_2) -alkyl optionally substituted in the aryl radical or (C_3-C_2) -cycloalkyl;
- R³ is hydrogen, (C₁-C₈)-alkyl, op ionally substituted (C₆-C₁₄)-aryl, (C₂-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical (C₂-C₈)-cycloalkyl, (C₂-C₈)-alkenyl, (C₂-C₈)-alkenyl, (C₂-C₈)-alkynyl, (C₂-C₈)-alkynylcarbonyl, pyridyl, R¹¹NH, R⁴CO, COOR⁴, CON(CH₃)R¹⁴, CON(HR¹⁴, CON(HR¹⁴, CON(HR¹⁵);
- R⁴ is hydrogen or (C₁-C₂₈)-alkyl which can optionally be mono- or polysubstituted by identical or different radicals R⁴; R⁴ is hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or di
 ((C₁-C₁₈)-alkyl)aminocarbonyl amino-(C₂-C₁₈)-alkylaminocarbonyl, amino-(C₁-C₃)
 alkylphenyl-(C₁-C₃)-alkylaminocarbonyl, (C₁-C₁₈)-alkylcarbonylamino-(C₁-C₃)-alkylphenyl
 (C₁-C₃)-alkylaminocarbonyl, (C₁-C₁₈)-alkylcarbonylamino-(C₂-C₁₈)-alkylaminocarbonyl,

 (C₂-C₁₄)-aryl-(C₁-C₈)-alkoxycarbonyl which can also be substituted in the aryl radical,

 amino, mercapto, (C₁-C₁₈)-alkoxyc. (C₁-C₁₈)-alkoxycarbonyl, optionally substituted

 (C₂-C₈)-cycloalkyl, halogen, nitro, trifluoromethyl or the radical R⁵;
- R⁵ is optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical, a mono- or bi cyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated or completely hydrogenated and which can contain one, two or three identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur, a radical R³ or a radical R⁶CO-, where the aryl radical and, independently thereof, the heterocyclic radical can be mono- or polysubstituted by identical or different radicals from the group consisting of (C₁-C₁₈)-alkyl, (C₁-C₁₈)-alkoxy, halogen, nitro, amino and trifluoromethyl;
- R⁶ is R⁷R⁸N, R⁷O or R⁷S or an antino acid side chain, a natural or unnatural amino acid, imino acid, optionally N-(C₁-C₂)-alkylated or N-((C₅-C₁₄)-aryl-(C₁-C₈)-alkylated) azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to -NH-CH₂-, and their esters and amides, where hydrogen or

hydroxymethyl can optionally stand in place of free functional groups and/or where free functional groups can be protected by protective groups customary in peptide chemistry;

- R⁷ is hydrogen, (C₁-C₁₈)-alkyl, (C₁-C₁₄)-aryl-(C₁-C₈)-alkyl, (C₁-C₁₈)-alkylcarbonyl, (C₁-C₁₈)-alkylcarbonyl, (C₁-C₁₄)-aryl-aryl-(C₁-C₈)-alkylcarbonyl or (C₂-C₁₄)-aryl-aryl-(C₁-C₁₈)-alkyloxycarbonyl, where the alkyl groups/can optionally be substituted by an amino group and/or where the aryl radicals can be mono- or polysubstituted, preferably monosubstituted, by identical or different radicals from the group consisting of (C₁-C₈)-alkyl, (C₁-C₈)-alkoxy, halogen, nitro, amino and trifluoromethyl, or is a natural or unnatural amino acid, imino acid, optionally N-(C₁-C₈)-alkylated or N-((C₅-C₁₄)-aryl-(C₁-C₈)-alkylated) azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or in which the peytide bond can be reduced to -NH-CH₂-;
- R⁸ is hydrogen, (C_1-C_{18}) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl which can also be substituted in the aryl radical;
- R⁹ is hydrogen, aminocarbonyl, (C₁-C₁₈) alkylaminocarbonyl,

 (C₃-C₈)-cycloalkylaminocarbonyl, optionally substituted (C₆-C₁₄)-arylaminocarbonyl, (C₁-C₁₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl or (C₃-C₈)-cycloalkyl;
- is hydroxyl, (C_1-C_{18}) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;
- R¹¹ is hydrogen, (C_1-C_{18}) -alkyl, $I_1^{12}CO$, optionally substituted (C_6-C_{14}) -aryl- $S(O)_2$, (C_1-C_{18}) -alkyl- $S(O)_2$, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or $R^9NHS(O)_2$;
- is hydrogen, (C_1-C_{18}) -alkyl, (C_2-C_8) -alkenyl, (C_2-C_8) -alkynyl, optionally substituted (C_6-C_{14}) -aryl, (C_1-C_{18}) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;
- R¹³ is hydrogen, (C₁-C₆)-alkyl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical or (C₃-C₈)-cycloalkyl;
- R¹⁴ is hydrogen or (C₁-C₂₈)-alkyl which can optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxyl, hydroxycarbonyl,

aminocarbonyl, mono- or di- $((C_1-C_{18})-alkyl)-aminocarbonyl.$ amino- $(C_2-C_{18})-alkylaminocarbonyl.$ amino- $(C_1-C_2)-alkylphenyl-<math>(C_1-C_3)-alkylaminocarbonyl.$ $(C_1-C_{18})-alkylcarbonylamino-<math>(C_1-C_2)-alkylphenyl-(C_1-C_3)-alkylaminocarbonyl.$ $(C_1-C_{18})-alkylaminocarbonyl.$ $(C_2-C_{18})-alkylaminocarbonyl.$ $(C_3-C_{14})-aryl-(C_1-C_3)-alkoxycarbonyl$ which can also be substituted in the aryl radical, amino, mercapto, $(C_1-C_{18})-alkoxy.$ $(C_1-C_{18})-alkoxy.$ $(C_1-C_{18})-alkoxy.$ $(C_1-C_2)-alkyl.$ $(C_1-C_2)-alkyl.$

 R^{15} is R^{16} -(C_1 - C_6)-alkyl or R^{16} :

unsaturated and which can also contain one to four identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur and which can also be substituted by one or more identical or different substituents from the group consisting of (C₁-C₄)-alkyl and oxo;

b, c, and d are 1;

e is 0, 1, 2, 3, 4, 5 or 6;


f is 0;

g is 0, 1, 2, 3, 4, 5 or 6;

h is 0, 1, 2, 3, 4, 5 or 6;

in all their stereoisomeric forms and mixtures thereof in any ratio, and of their physiologically tolerable salts.

23. (amended) A method for treating or preventing a disease or disorder selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, inflammatory disorders of the central nervous system, asthma, allergies, cardiovascular disorders, ateriosclerosis, restenoses, diabetes, damage to organ transplants, tumor growth, tumor metastasis, and malaria comprising administering to a subject in need thereof an effective amount of [the preparation as claimed in claim 1] a preparation comprising an effective amount of at least one compound of the formula I:



in which

W is R^1 -A-C(R^{13}) < :

Y is a carbonyl;

Z is $N(R^0)$:

A is a bivalent radical from the group consisting of (C_1-C_5) -alkylene, (C_3-C_7) -cycloalkylene, phenylene, phenylene, (C_1-C_5) -alkylenephenyl, phenylene- (C_2-C_5) -alkenyl or a bivalent radical of a 5- or 6- numbered saturated or unsaturated ring which can contain 1 or 2 nitrogen atoms and can be mono- or disubstituted by (C_1-C_5) -alkyl or doubly bonded oxygen or sulfur:

B is a bivalent radical from the roup consisting of (C_1-C_6) -alkylene, (C_2-C_6) -alkenylene, phenylene, phenylene- (C_1-C_4) -alkyl, (C_1-C_2) -alkylenephenyl, where the bivalent (C_1-C_6) -alkylene radical can be unsubstituted or substituted by a radical from the group consisting of (C_1-C_8) -alkyl, (C_2-C_8) -alkenyl, (C_2-C_8) -alkynyl, (C_3-C_{10}) -cycloalkyl, (C_3-C_{10}) -cycloalkyl- (C_1-C_6) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl and heteroaryl- (C_1-C_6) -alkyl optionally substituted in the heteroaryl radical:

D is $C(R^2)(R^3)$, $N(R^3)$ or $CH = C(R^3)$;

E is R¹⁰CO;

R is hydrogen, (C_1-C_2) -alkyl, (C_3-C_2) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_2) -alkyl optionally substituted in the aryl radical;

R⁰ is hydrogen, (C_1-C_8) -alkyl, (C_1-C_{12}) -cycloalkyl, (C_3-C_{12}) -cycloalkyl, (C_1-C_8) -alkyl, (C_6-C_{12}) -bicycloalkyl, (C_6-C_{12}) -bicycloalkyl, (C_6-C_{12}) -tricycloalkyl, (C_6-C_{12}) -tricycloalkyl, (C_6-C_{12}) -tricycloalkyl, (C_6-C_{12}) -aryl, (C_6-C_{12}) -aryl, (C_6-C_{12}) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl, heteroaryl- (C_1-C_8) -alkyl optionally substituted in the heteroaryl radical, CHO, (C_1-C_8) -alkyl-CO, (C_3-C_{12}) -

eycloalkyl-CO, (C_2-C_{12}) -cycloalkyl- (C_1-C_2) -alkyl-CO, (C_5-C_{12}) -bicycloalkyl-CO, (C_5-C_{12}) -tricycloalkyl-CO, (C_5-C_{12}) -tricycloalkyl-CO, optionally substituted (C_5-C_{12}) -aryl-CO, (C_5-C_{12}) -aryl-CO, tricycloalkyl-CO optionally substituted in the aryl radical, optionally substituted heteroaryl-CO, heteroaryl-CO, heteroaryl-CO, heteroaryl-CO, alkyl-CO optionally substituted in the heteroaryl radical, (C_1-C_2) -alkyl-S(O)₁, (C_2-C_{12}) -alkyl-S(O)₂, (C_3-C_{12}) -bicycloalkyl-S(O)₃, (C_3-C_{12}) -cycloalkyl-S(O)₄, (C_3-C_{12}) -bicycloalkyl-S(O)₅, (C_5-C_{12}) -bicycloalkyl-S(O)₆, (C_5-C_{12}) -bicycloalkyl-S(O)₇, (C_5-C_{12}) -tricycloalkyl-S(O)₈, (C_5-C_{12}) -tricycloalkyl-S(O)₁, (C_5-C_{12}) -aryl-S(O)₁, (C_5-C_{12}) -aryl-S(O)₂, (C_5-C_{12}) -aryl-S(O)₃, optionally substituted in the aryl radical, optionally substituted heteroaryl radical, optionally substituted in the heteroaryl radical, where n is 1 or 2:

<u>R</u>¹ is X-NH-C(=NH)-(CH₂)_p or Σ^{1} -NH-(CH₂)_p, where p is 0, 1, 2 or 3;

- X is hydrogen, (C_1-C_6) -alkyl, (C_1, C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_6) -alkoxycarbonyl, optionally substituted (C_6-C_{14}) -arylcarbonyl, optionally substituted $(C_$
- X^1 has one of the meanings of X or is/R'-NH-C(=N-R''), where R' and R'' independently of one another have the meanings of X;
- R² is hydrogen, (C_1-C_8) -alkyl, op ionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or (C_3-C_8) -cycloalkyl;
- R³ is hydrogen; (C₁-C₈)-alkyl, op ionally substituted (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical, (C₂-C₈)-cycloalkyl, (C₂-C₈)-alkenyl, (C₂-C₈)-alkenyl, (C₂-C₈)-alkynyl, (C₂-C₈)-alkynylcarbonyl, pyridyl, R¹¹NH, R⁴CO.

 COOR⁴, CON(CH₂)R¹⁴, CON)HR¹⁴, CSNHR¹⁴, COOR¹⁵, CON(CH₂)R¹⁵ or CONHR¹⁵;
- R⁴ is hydrogen or (C_1-C_{2R}) -alkyl which can optionally be mono- or polysubstituted by identical or different radicals R⁴: R⁴ is hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or di- $((C_1-C_{1R})$ -alkyl)aminocarbonyl amino- (C_2-C_{1R}) -alkylaminocarbonyl, amino- (C_1-C_3) -alkylphenyl- (C_1-C_3) -alkylaminocarbonyl, (C_1-C_{1R}) -alkylcarbonylamino- (C_1-C_3) -alkylphenyl-

 (C_1-C_2) -alkylaminocarbonyl, (C_1-C_{18}) -alkylcarbonylamino- (C_2-C_{18}) -alkylaminocarbonyl, (C_5-C_{14}) -aryl- (C_1-C_2) -alkoxycarbonyl which can also be substituted in the aryl radical, amino, mercapto, (C_1-C_{18}) -alkoxy, (C_1-C_{18}) -alkoxycarbonyl, optionally substituted (C_2-C_2) -cycloalkyl, halogen, nitro, trifluoromethyl or the radical \mathbb{R}^5 :

ks is optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical, a mono- or bicyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated or completely hydrogenated and which can contain one, two or three identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur, a radical R⁶ or a radical R⁶CO-, where the aryl radical and, independently thereof, the heterocyclic radical can be mono- or polysubstituted by identical or different radicals from the group consisting of (C₁-C₁₈)-alkyl, (C₁-C₁₈)-alkoxy, halogen, mitro, amino and trifluoromethyl;

R⁶ is R⁷R⁸N, R⁷O or R⁷S or an arnino acid side chain, a natural or unnatural amino acid, imino acid, optionally N-(C₁-C₈)-alk/lated or N-((C₅-C₁₄)-aryl-(C₁-C₈)-alkylated) azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to NH-CH₂-, and their esters and amides, where hydrogen or hydroxymethyl can optionally stand in place of free functional groups and/or where free functional groups can be projected by protective groups customary in peptide chemistry;

R⁷ is hydrogen, (C₁-C₁₈)-alkyl, (C₁-C₁₄)-aryl-(C₁-C₈)-alkyl, (C₁-C₁₈)-alkylcarbonyl, (C₁-C₁₈)-alkylcarbonyl, (C₁-C₁₈)-alkylcarbonyl, (C₁-C₁₈)-alkylcarbonyl or (C₂-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl or (C₂-C₁₄)-aryl-(C₁-C₁₈)-alkyloxycarbonyl, where the alkyl groups can optionally be substituted by an amino group and/or where the aryl radicals can be mono- or polysubstituted, preferably monosubstituted, by identical or different radicals from the group consisting of (C₁-C₈)-alkyl, (C₁-C₈)-alkoxy, halogen, nitro, amino and trifluoromethyl, or is a natural or unnatural amino acid, imino acid, optionally N-(C₁-C₈)-alkylated or N-((C₂-C₁₄)-aryl-(C₁-C₈)-alkylated) azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to -NH-CH₂-;

R⁸ is hydrogen, $(C_1 - C_{18})$ -alkyl, or tionally substituted $(C_6 - C_{14})$ -aryl or $(C_6 - C_{14})$ -aryl- $(C_1 - C_8)$ alkyl which can also be substituted in the aryl radical;

- R⁹ is hydrogen, aminocarbonyl, (C_1-C_{18}) -alkylaminocarbonyl, (C_2-C_{2}) -cycloalkylaminocarbonyl, optionally substituted (C_2-C_{14}) -arylaminocarbonyl, (C_1-C_{18}) -alkyl, optionally substituted (C_2-C_{14}) -aryl or (C_2-C_{2}) -cycloalkyl;
- R¹⁰ is hydroxyl, (C_1-C_{18}) -alkoxy, (C_5-C_{14}) -aryl- (C_1-C_8) -alkoxy which can also be substituted in the aryl radical, optionally st betituted (C_5-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;
- R¹¹ is hydrogen, (C_1-C_{18}) -alkyl, R^{12} CO, optionally substituted (C_5-C_{14}) -aryl- $S(O)_2$, (C_1-C_{18}) -alkyl- $S(O)_2$, (C_5-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or $R^9NHS(O)_2$;
- R¹² is hydrogen, (C₁-C₁₈)-alkyl, (C₂-C₃)-alkenyl, (C₂-C₈)-alkynyl, optionally substituted (C₆-C₁₄)-aryl, (C₁-C₁₈)-alkoxy, (C₆-C₁₄)-aryl-(C₁-C₈)-alkoxy which can also be substituted in the aryl radical, optionally substituted (C₆-C₁₄)-aryloxy, amino or mono- or di-((C₁-C₁₈)-alkyl)amino;
- R¹³ is hydrogen, (C_1-C_5) -alkyl, $((C_1-C_{14})$ -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or (C_3-C_8) -cycloalkyl,
- identical or different radicals from the group consisting of hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or di- (C₁-C₁₈)-alkyl)-aminocarbonyl, amino-(C₂-C₁₈)-alkylaminocarbonyl, amino-(C₁-C₃)-alkylphenyl-(C₁-C₃)-alkylaminocarbonyl, (C₁-C₁₈)-alkylcarbonylamino-(C₁-C₃)-alkylphenyl-(C₁-C₃)-alkylaminocarbonyl, (C₁-C₁₈)-alkylcarbonylamino-(C₂-C₁₈)-alkylaminocarbonyl, (C₂-C₁₄)-aryl-(C₁-C₂)-alkoxycarbonyl which can also be substituted in the aryl radical, amino, mercapto, (C₁-C₁₈)-alkoxycarbonyl optiona ly substituted (C₂-C₂)-cycloalkyl, HOS(O)₂-(C₁-C₃)-alkyl, R⁹NHS(O)₂-(C₁-C₃)-alkyl, (R O)₂P(O)-(C₁-C₃)-alkyl, tetrazolyl-(C₁-C₃)-alkyl, halogen, nitro, trifluoromethyl and R⁵:

 R^{15} is R^{16} -(C_1 - C_6)-alkyl or R^{16} .

R¹⁶ is a 6- to 24-membered bicyclic or tricyclic radical which is saturated or partially

unsaturated and which can also contain one to four identical or different heteroatoms from
the group consisting of nitrogen, oxygen and sulfur and which can also be substituted by

10/14/99 THU 22;34 FAX 6391

one or more identical or different substituents from the group consisting of (C_1-C_4) -alkyl and oxo;

b, c, and d are 1;

e is 0, 1, 2, 3, 4, 5 or 6;

f is 0;

g is 0, 1, 2, 3, 4, 5 or 6;

h is 0, 1, 2, 3, 4, 5 or 6;

in all their stereoisomeric forms and mixtures thereof in any ratio, and of their physiologically tolerable salts.

24. (amended) A method for the treatment or prophylaxis of diseases in which leucocyte adhesion and/or migration exhibits an undesired extent comprising administering to a subject in need thereof an effective amount of the preparation as claimed in claim 1] a preparation comprising an effective amount of at least/one compound of the formula I:

$$\begin{array}{c|c}
C & C & C \\
W & C \\
Z & Y & C
\end{array}$$

$$\begin{array}{c|c}
C & C \\
(CH_2)_e & CC)_f & (CH_2)_g & D & (CH_2)_h & E
\end{array}$$

$$\begin{array}{c|c}
C & C \\
C & C$$

in which

W is R^1 -A-C(R^{13}) <;

Y is a carbonyl;

Z is $N(R^0)$;

A is a bivalent radical from the group consisting of (C_1-C_5) -alkylene, (C_3-C_7) -cycloalkylene, phenylene, phenylene, (C_1-C_5) -alkyl, (C_1-C_5) -alkylenephenyl, phenylene- (C_7-C_5) -alkenyl or a bivalent radical of a/5- or 6-inembered saturated or unsaturated ring which can contain 1 or 2 nitrogen atoms and can be mono- or disubstituted by (C_1-C_5) -alkyl or doubly bonded oxygen or sulfur:

B is a bivalent radical from the group consisting of (C_1-C_2) -alkylene, (C_2-C_2) -alkenylene, phenylene, phenylene- (C_1-C_2) -alkyl, (C_1-C_2) -alkylenephenyl, where the bivalent (C_1-C_2) -alkylenephenyl, where the bivalent (C_1-C_2) -alkylenephenyl

alkylene radical can be unsubstituted or substituted by a radical from the group consisting of (C_1-C_2) -alkyl, (C_2-C_3) -alkeryl, (C_2-C_3) -alkynyl, (C_3-C_{10}) -cycloalkyl, (C_3-C_{10}) -cycloalkyl- (C_1-C_3) -alkyl, optionally substituted (C_4-C_{14}) -aryl, (C_5-C_{14}) -aryl- (C_1-C_3) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl and heteroaryl- (C_1-C_3) -alkyl optionally substituted in the heteroaryl radical;

D is $C(R^2)(R^3)$, $N(R^3)$ or $CH = C(R^3)$;

E is $R^{10}CO$:

R is hydrogen, (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical:

 $\underline{R^0}$ is hydrogen, $(\underline{C_1}-\underline{C_2})$ -alkyl, $(\underline{C_1}-\underline{C_{12}})$ -cycloalkyl, $(\underline{C_3}-\underline{C_{12}})$ -cycloalkyl, $(\underline{C_1}-\underline{C_2})$ -alkyl, $(\underline{C_2}-\underline{C_{12}})$ bicycloalkyl, (C_6-C_{12}) -bicyclos lkyl/ (C_1-C_8) -alkyl, (C_6-C_{12}) -tricycloalkyl, (C_6-C_{12}) - $\underline{\text{tricycloalkyl-}(C_1-C_2)-\text{alkyl. op:ionally substituted }(C_6-C_{14})-\text{aryl-}(C_1-C_2)-\text{alkyl.}}$ optionally substituted in the aryl radical, optionally substituted heteroaryl, heteroaryl-(C1- C_g)-alkyl optionally substitute in the heteroaryl radical, CHO, (C_1-C_g) -alkyl-CO, (C_2-C_{12}) cycloalkyl-CO, (C_3-C_{12}) -cyc/o:ulkyl- (C_1-C_2) -alkyl-CO, (C_6-C_{12}) -bicycloalkyl-CO, (C_6-C_{12}) bicycloalkyl- (C_1-C_2) -alkyl- (C_6-C_{12}) -tricycloalkyl-CO, (C_6-C_{12}) -tricycloalkyl- (C_1-C_2) -alkyl-CO, optionally substituted (C_5-C_{14}) -aryl-CO, (C_5-C_{14}) -aryl- (C_1-C_2) -alkyl-CO optionally substituted in the aryl radical, optionally substituted heteroaryl-CO, heteroaryl-(C1-C2)-alkyl-CO optionally st bstituted in the heteroaryl radical, (C1-C3)-alkyl-S(O)1, $\underline{(C_3-C_{12})-\text{cycloalkyl-S}(\phi)_{\underline{n}},\ (C_{\underline{3}^-}C_{\underline{12}})-\text{cycloalkyl-}(C_{\underline{1}^-}C_{\underline{g}})-\text{alkyl-S}(O)_{\underline{n}},\ (C_{\underline{6}^-}C_{\underline{12}})-\text{bicycloalkyl-}}$ $\underline{S(O)_n}$, $(\underline{C_6}-\underline{C_{12}})$ -bicyc/oalkyl- $(\underline{C_1}-\underline{C_2})$ -alkyl- $\underline{S(O)_n}$, $(\underline{C_6}-\underline{C_{12}})$ -tricycloalkyl- $\underline{S(O)_n}$, $(\underline{C_6}-\underline{C_{12}})$ - $\underline{\text{tricycloalkyl-}(C_1-C_2)}$ -alkyl- $\underline{S(C)_0}$, optionally substituted $\underline{(C_2-C_{14})}$ -aryl- $\underline{S(O)_0}$, $\underline{(C_2-C_{14})}$ -aryl- $\underline{S(O)_0}$, $\underline{(C_2-C_{14})}$ -aryl- $\underline{S(O)_0}$ (C₁-C₈)-alkyl-S(O), optionally substituted in the aryl radical, optionally substituted heteroaryl-S(O), or heteroaryl (C1-C2)-alkyl-S(O), optionally substituted in the heteroaryl radical, where n is 1 or 2;

 R^1 is X-NH-C(=NH)-(CH₂)_p or X^1 -NH-(CH₂)_p, where p is 0, 1, 2 or 3;

X is hydrogen (C_1-C_6) -alkyl, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_6) -alkoxycarbonyl, optionally substituted (C_6-C_{14}) -arylcarbonyl, optionally substituted (C_6-C_{14}) -aryloxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl which can also be substituted in the aryl radical, $(R^8O)_2P(O)$, cyano, hydroxyl, (C_1-C_6) -

- X^1 has one of the meanings of X or is R'-NH-C(=N-R''), where R' and R'' independently of one another have the meanings of X;
- R² is hydrogen, (C_1-C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or (C_3-C_8) -cycloalkyl;
- R³ is hydrogen, (C₁-C₂)-alkyl, op ionally substituted (C₂-C₁₄)-aryl, (C₂-C₁₄)-aryl-(C₁-C₂)-alkyl optionally substituted in the aryl radical, (C₂-C₂)-cycloalkyl, (C₂-C₂)-alkenyl, (C₂-C₂)-alkynyl, (C₂-C₂)-alkynyl, (C₂-C₂)-alkynylcarbonyl, pyridyl, R¹¹NH, R⁴CO, COOR⁴, CON(CH₂)R¹⁴, CON JR¹⁴, CSNHR¹⁴, COOR¹⁵, CON(CH₂)R¹⁵ or CONHR¹⁵;
- R⁴ is hydrogen or (C₁-C₂₈)-alkyl which can optionally be mono- or polysubstituted by identical or different radicals R⁴; R⁴ is hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or di
 ((C₁-C₁₈)-alkyl)aminocarbonyl amino-(C₂-C₁₈)-alkylaminocarbonyl, amino-(C₁-C₃)
 alkylphenyl-(C₁-C₃)-alkylaminocarbonyl, (C₁-C₁₈)-alkylcarbonylamino-(C₁-C₃)-alkylphenyl
 (C₁-C₃)-alkylaminocarbonyl, (C₁-C₁₈)-alkylcarbonylamino-(C₂-C₁₈)-alkylaminocarbonyl,

 (C₅-C₁₄)-aryl-(C₁-C₈)-alkoxycarbonyl which can also be substituted in the aryl radical,

 amino, mercapto, (C₁-C₁₈)-alkyxy, (C₁-C₁₈)-alkoxycarbonyl, optionally substituted

 (C₃-C₈)-cycloalkyl, halogen, nitro, trifluoromethyl or the radical R⁵;
- R⁵ is optionally substituted (C₆-C₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl optionally substituted in the aryl radical, a mono- or bicyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated or completely hydrogenated and which can contain one, two or three identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur, a radical R⁵ or a radical R⁶CO-, where the aryl radical and, independently thereof, the heterocyclic radical can be mono- or polysubstituted by identical or different radicals from the group consisting of (C₁-C₁₈)-alkyl, (C₁-C₁₈)-alkoxy, halogen, nitro, amino and trifluoromethyl;
- R⁵ is R⁷R⁸N. R⁷O or R²S or an amino acid side chain, a natural or unnatural amino acid, imino acid, optionally N-(C₁-C₈)-alkylated or N-((C₅-C₁₄)-aryl-(C₁-C₈)-alkylated) azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to -NH-CH₂₋₁ and their esters and amides, where hydrogen or

-17-

hydroxymethyl can optionally stand in place of free functional groups and/or where free functional groups can be protected by protective groups customary in peptide chemistry:

- R⁷ is hydrogen. (C₁-C₁₈)-alkyl, (C₂-C₁₄)-aryl-(C₁-C₂)-alkyl, (C₂-C₁₈)-alkylcarbonyl, (C₁-C₁₈)-alkylcarbonyl, (C₁-C₁₈)-alkylcarbonyl, (C₁-C₁₄)-aryl-(C₁-C₁₈)-alkylcarbonyl or (C₆-C₁₄)-aryl-(C₁-C₁₈)-alkyloxycarbonyl, where the alkyl groups can optionally be substituted by an amino group and/or where the aryl radicals can be mono- or polysubstituted, preferably monosubstituted, by identical or different/radicals from the group consisting of (C₁-C₈)-alkyl, (C₁-C₈)-alkoxy, halogen, nitro, amino and trifluoromethyl, or is a natural or unnatural amino acid, imino acid, optionally N-(C₁-C₈)-alkylated or N-((C₆-C₁₄)-aryl-(C₁-C₈)-alkylated) azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to -NH-CH₂-:
- R⁸ is hydrogen, (C_1-C_{18}) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl which can also be substituted in the aryl radical;
- R⁹ is hydrogen, aminocarbonyl, (C_1-C_{18}) -alkylaminocarbonyl, (C_3-C_8) -cycloalkylaminocarbonyl, optionally substituted (C_6-C_{14}) -arylaminocarbonyl. (C_1-C_{18}) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_3-C_8) -cycloalkyl;
- R¹⁰ is hydroxyl, (C_1-C_{18}) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;
- R¹¹ is hydrogen, (C_1-C_{18}) -alkyl, $R^{12}CO$, optionally substituted (C_6-C_{14}) -aryl- $S(O)_2$, (C_1-C_{18}) -alkyl- $S(O)_2$, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or $R^0NHS(O)_2$;
- Is hydrogen, (C_1-C_8) -alkyl, (C_2-C_8) -alkenyl, (C_2-C_8) -alkynyl, optionally substituted (C_6-C_{14}) -aryl, (C_1-C_{18}) -alkoxy. (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;
- R¹³ is hydrogen, (C_1-C_2) -alkyl, (C_2-C_{14}) -aryl- (C_1-C_2) -alkyl optionally substituted in the aryl radical or (C_3-C_3) -cycloalkyl;
- R¹⁴ is hydrogen or (C₁-C₂₈)-alkyl which can optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxyl, hydroxycarbonyl,

بالملطان والمستحدث والمستحدث

aminocarbonyl, mono- or di- $((C_1-C_{18})$ -alkyl)-aminocarbonyl, amino- (C_2-C_{18}) -alkylaminocarbonyl, amino- (C_1-C_2) -alkylphenyl- (C_1-C_3) -alkylaminocarbonyl, (C_1-C_{18}) -alkylcarbonylamino- (C_1-C_3) -alkylphenyl- (C_1-C_3) -alkylaminocarbonyl, (C_1-C_{18}) -alkylcarbonyl-amino- (C_2-C_{18}) -alkylaminocarbonyl, (C_5-C_{14}) -aryl- (C_1-C_8) -alkoxycarbonyl which can also be substituted in the aryl radical, amino, mercapto, (C_1-C_{18}) -alkoxy, (C_1-C_{18}) -alkoxycarbonyl, optionally substituted (C_3-C_8) -cycloalkyl, (C_5-C_1) -alkyl, (C_5-C_1) -alkyl, (C_5-C_1) -alkyl, (C_5-C_2) -alkyl, (C_5-C_3) -alkyl,

nitro, trifluoromethyl and R

 R^{15} is R^{16} -(C_1 - C_2)-alkyl or R^{16}

R¹⁶ is a 6- to 24-membered bicyclic or tricyclic radical which is saturated or partially unsaturated and which can also contain one to four identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur and which can also be substituted by one or more identical or different substituents from the group consisting of (C₁-C₄)-alkyl and oxo;

b, c, and d are 1;

e is 0. 1. 2. 3, 4, 5/or 6;

f is 0;

g is 0, 1, 2, 3, 4, 5 or 6;

h is 0, 1, 2, 3/4, 5 or 6;

in all their stereoisomeric forms and mixtures thereof in any ratio, and of their physiologically tolerable salts.

Please add the following claims:

- 39. The method as claimed in claim 21, wherein

is a bivalent radical from the group consisting of (C_1-C_6) -alkylene, (C_3-C_7) cycloalkylene, phenylene, phenylene- (C_1-C_6) -alkyl, (C_1-C_6) -alkylenephenyl, phenylene- (C_2-C_6) -alkenyl or a bivalent radical of a 5- or 6-membered saturated or unsaturated
ring which can contain 1 or 2 nitrogen atoms and can be mono- or disubstituted by (C_1-C_6) -alkyl or doubly bonded oxygen or sulfur;

 (C_1-C_8) -alkoxycarbonyl which can also be substituted in the aryl radical, amino, mercapto, (C_1-C_{18}) -alkoxy, (C_1-C_{18}) -alkoxycarbonyl, optionally substituted (C_3-C_8) -cycloalkyl, halogen, nitro, trifluoromethyl or the radical R^5 ;

is optionally substituted (C_6 - C_{14})-aryl, (C_6 - C_{14})-aryl-(C_1 - C_8)-alkyl optionally substituted in the aryl radical, a mono- or bicyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated or completely hydrogenated and which can contain one, two or three identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur, a radical R^6 or a radical R^6 CO-, where the aryl radical and, independently thereof, the heterocyclic radial can be mono- or polysubstituted by identical or different radicals from the group consisting of (C_1 - C_{18})-alkyl, (C_1 - C_{18})-alkoxy, halogen, nitro, amino or trifluoromethyl;

is R^7R^8N , R^7O or R^7S or an amino acid side chain, a natural or unnatural amino acid, imino acid, optionally $N-(C_1-C_8)$ -alkylated or $N-((C_6-C_{14})$ -aryl- (C_1-C_8) -alkylated) azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to $-NH-CH_2-$, and their esters and amides, where hydrogen or hydroxymethyl can optionally stand in place of free functional groups and/or where free functional groups can be protected by protective groups customary in peptide chemistry;

R⁷ is hydrogen, (C_1-C_{18}) -alkyl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl, (C_1-C_{18}) -alkylcarbonyl, (C_6-C_{14}) -aryl-aryl- (C_1-C_8) -alkylcarbonyl, (C_6-C_{14}) -aryl-aryl- (C_1-C_8) -alkylcarbonyl or (C_6-C_{14}) -aryl- (C_1-C_{18}) -alkyloxycarbonyl, where the alkyl groups can optionally be substituted by an amino group and/or where the aryl radicals can be mono-or polysubstituted by identical or different radicals from the group consisting of (C_1-C_8) -alkyl, (C_1-C_8) -alkoxy, halogen, nitro, amino and trifluoromethyl, or is a natural or unnatural amino acid, imino acid, optionally N- (C_1-C_8) -alkylated or N- $((C_6-C_{14})$ -aryl (C_1-C_8) -alkylated) azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to -NH-CH₂₋₇.

R⁸ is hydrogen, (C_1-C_{18}) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl which can also be substituted in the aryl radical;

R⁹ is hydrogen, aminocarbonyl, (C_1-C_{18}) -alkylaminocarbonyl, (C_3-C_8) -cycloalkylaminocarbonyl, optionally substituted (C_6-C_{14}) -arylaminocarbonyl, (C_1-C_{18}) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_3-C_8) -cycloalkyl;

R¹⁰ is hydroxyl, (C_1-C_{18}) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;

R¹¹ is hydrogen, (C_1-C_{18}) -alkyl, R¹²CO, optionally substituted (C_6-C_{14}) -aryl-S(O)₂, (C_1-C_{18}) -alkyl-S(O)₂, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or R⁹NHS(O)₂;

is hydrogen, (C_1-C_{18}) -alkyl, (C_2-C_8) -alkeryl, (C_2-C_8) -alkynyl, optionally substituted (C_6-C_{14}) -aryl, (C_1-C_{18}) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;

R¹³ is hydrogen, (C_1-C_6) -alkyl. (C_6-C_1) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or (C_3-C_8) -cycloalkyl;

is hydrogen or (C_1-C_{28}) -alltyl which can optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxyl, hydroxycarbonyl, amino-arbonyl, mono- or di- $((C_1-C_{18})$ -alkyl)aminocarbonyl, amino- (C_2-C_{18}) -alkylaminocarbonyl, amino- (C_1-C_1) -alkylphenyl- (C_1-C_8) -alkylaminocarbonyl, (C_1-C_{18}) -alkylcarbonylamino- (C_1-C_3) -alkylphenyl- (C_1-C_3) -alkylaminocarbonyl, (C_1-C_{18}) -alkylcarbonylamino- (C_2-C_{18}) -alkylaminocarbonyl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxycarbonyl which can also be substituted in the aryl radical, amino, mercapto, (C_1-C_{18}) -alkoxy, (C_1-C_{18}) -alkoxycarbonyl, optionally substituted (C_3-C_8) -cycloalkyl, (C_1-C_3) -alkyl, (C_1-C_3) -alkyl, halogen, nitro, trifluoromethyl and (C_3-C_3) -alkyl, tetrazolyl- (C_1-C_3) -alkyl, halogen, nitro,

 R^{15} is R^{16} -(C_1 - C_6)-alkyl or R^{16} ;

R¹⁶ is a 6- to 24-membered bicyclic or tricyclic radical which is saturated or partially unsaturated and which can also contain one to four identical or different heteroatoms from the

group consisting of nitrogen, oxygen and sulfur and which can also be substituted by one or more identical or different substituents from the group consisting of (C_1-C_4) -alkyl and oxo; b, c, and d independently of one another are 0 or 1, but cannot all simultaneously be 0; e, g and h independently of one another are 0, 1, 2, 3, 4, 5 or 6; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

- 40. The method as claimed in claim 21, wherein R^0 is (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, (C_3-C_8) -cycloalkyl- (C_3-C_4) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.
- 41. The method as claimed in claim 40, wherein R⁰ is biphenylylmethyl, naphthylmethyl or benzyl each of which is unsubstituted or monosubstituted or polysubstituted in the aryl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

42. The method as claimed in claim 21, wherein

B is a bivalent radical from the group consisting of methylene, ethylene, trimethylene, tetramethylene, vinylene, phenylene, or is substituted methylene or ethylene;

R is hydrogen, (C_1-C_6) -alkyl or benzyl;

R⁰ is (C_1-C_8) -alkyl, (C_3-C_8) -c./cloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl-aryl-aryl-alkyl optionally substituted in the aryl radical;

is X-NH-C(=NH), X-NH-C(=NX)-NH or X-NH-CH₂;



X is hydrogen, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_8) -alkylcarbonyloxy- (C_1-C_6) -alkoxycarbonyl, (C_6-C_{14}) -aryl- (C_1/C_6) -alkoxycarbonyl or hydroxyl;

 R^2 is hydrogen or (C_1-C_8) -alkyl;

R³ is (C_1-C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, (C_2-C_8) -alkenyl, (C_2-C_8) -alkynyl, pyridyl, R¹¹NH, R⁴CO, COOR⁴, CONHR¹⁴, CSNHR¹⁴, COOR¹⁵ and CONHR¹⁵;

and e, g and h independently of one another are the numbers 0, 1, 2 or 3; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or/as their physiologically tolerable salts.

43. The method as claimed in claim 21, wherein W is R^1 -A-C(R^{13}) and R^{13} is (C_1 - C_6)-alkyl, (C_6 - C_{14})-aryl-(C_1 - C_8)-alkyl optionally substituted in the aryl radical or (C_3 - C_8)-cycloalkyl; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

44. The method as claimed in claim 21, wherein R^3 is optionally substituted (C_6-C_{14}) -aryl, COOR⁴, R^{11} NH or CONHR⁴, where -NHR¹⁴ is the radical of an α -amino acid, its ω -amino- (C_2-C_8) -alkylamide, its (C_1-C_8) -alkyl ester or its (C_6-C_{14}) -aryl- (C_1-C_4) -alkyl ester; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

45. The method as claimed in claim 44, wherein the radical of the α-amino acid is selected from the group consisting of value, lysine, phenylglycine, phenylalanine, tryptophan, and their (C₁-C₈)-alkyl esters or (C₆-C₁₄)-alkyl esters; wherein said compound or compounds may be present in all their stereor someric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable/salis.

46. The method as claimed in claim 21, wherein

Z is $N(R^0)$;

A is ethylene, trimethylene, tetramethylene, pentamethylene, cyclohexylene, phenylene or phenylenemethyl;

B is an unsubstituted or substituted methylene radical;

D is $C(\mathbb{R}^2)(\mathbb{R}^3)$;

R is hydrogen or (C_1-C_4) -alkyl;

R⁰ is (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl-aryl-aryl-alkyl optionally substituted in the aryl radical;

R¹ is $H_2N-C(=NH)$, $H_2N-C(\neq NH)-NH$ or H_2N-CH_2 ;

R² is hydrogen;

R³ is the radical CONHR¹⁴

 R^{10} is hydroxyl or $(C_1-C_8)/alk(xy)$;

 R^{13} is (C_1-C_6) -alkyl, (C_3/C_7) -cy/cloalkyl or benzyl;

 R^{14} is methyl which is substituted by hydroxycarbonyl and a radical from the group consisting of (C_1-C_4) -alkyl, phenyl and benzyl, or is methyl which is substituted by (C_1-C_8) -alkoxycarbonyl and a radical from the group consisting of (C_1-C_4) -alkyl, phenyl and benzyl; b, c and d are l and e and g are 0:

h is 1 or 2; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

47. The method as claimed in claim 21, wherein simultaneously W is R¹-A-C(R¹³) and therein A is a bivalent radical selected from the group consisting of methylene, ethylene, trimethylene, tetramethylene, pentamethylene, cyclohexylene, phenylene, phenylenemethyl;

is a bivalent radical from the group consisting of methylene, ethylene, trimethylene, В tetramethylene, vinylene, phenylene or is substituted/methylene or ethylene;

R is hydrogen or (C₁-C₆)-alkyl;

is (C_1-C_8) -alkyl, (C_3-C_8) -c/cloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- R^0 (C_1-C_8) -alkyl optionally substituted in the aryl radical;

is X-NH-C(=NH), X-NH-C(=NX)-NH or X-NH-CH₂; \mathbb{R}^1

X is hydrogen, (C₁-C₆)-alkylcarbonyl, (C₁-C₆)-alkoxycarbonyl, (C₁-C₈)-alkylcarbonyloxy- (C_1-C_6) -alkoxycarbonyl, (C_6-C_{14}) -aryl $/(C_1-C_6)$ -alkoxycarbonyl or hydroxyl;

is hydrogen or (C₁-C₈)-alky);

is CONHR¹⁵ or CONHR¹⁴/where R¹⁴ herein is a (C₁-C₈)-alkyl radical which is \mathbb{R}^3 unsubstituted or substituted by one or more (C₆-C₁₄)-aryl radicals;

is R^{16} - (C_1-C_6) -alkyl or R^{16} , where R^{16} is a 7- to 12-membered bridged bicyclic or R15 tricyclic radical which is saturated or partially unsaturated and which can also contain one to four identical or different/heteroa oms from the group consisting of nitrogen, oxygen and sulfur and which can also be substituted by one or more identical or different substituents from the group consisting of (C_1-C_4) -alkyl and oxo;

and e, g and h independently of one another are the numbers 0, 1, 2 or 3 and b, c and d are 1; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

48. The method as claimed in claim 47, wherein R15 is an adamantyl radical or an adamantylmethyl radical; whereir said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

-26-



49. The method as claimed in claim 21, wherein



A is ethylene, trimethylene, tetramethylene, pentamethylene, cyclohexylene, phenylene or phenylenemethyl;

B is an unsubstituted or substituted methylene radical;

D is $C(\mathbb{R}^2)(\mathbb{R}^3)$;

R is hydrogen or (C_1-C_4) -alkyl;

is (C_1-C_8) - alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical;

 R^1 is $H_2N-C(=NH)$, $H_2N-C(=NH)-NH$ or H_2N-CH_2 ;

R² is hydrogen;

R³ is CONHR¹⁵ or CONHR¹⁴ where R¹⁴ herein is a (C_1-C_6) -alkyl radical which is unsubstituted or substituted by one or more (C_6-C_{10}) -aryl radicals;

 R^{10} is hydroxyl or (C_1-C_8) -alkoxy;

 R^{13} is (C_1-C_6) -alkyl, (C_3-C_7) -c/reloalkyl or benzyl;

R¹⁵ is an adamantyl radical of an adamantylmethyl radical;

b, c and d are 1 and e and g are 0;

h is 1 or 2; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

50. The method as claimed in claim 21, wherein

A is ethylene, retramethylene, pentamethylene, cyclohexylene, phenylene, phen

B is an unsubstituted or substituted methylene radical or ethylene radical;

D is $C(R^2)(R^3)$;

R is hydrogen or C_1-C_4 -alkyl;

R° is (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl-aryl which is optionally substituted in the aryl radical;

R¹ is $H_2N-C(=NH)$, $H_2N-C(=NH)-NH$ or H_2N-CH_2 ;

R² is hydrogen;

is an unsubstituted phenyl radical or naphthyl radical, a phenyl radical or naphthyl radical substituted by one, two or three identical or different radicals from the group consisting of (C_1-C_4) -alkyl, (C_1-C_4) -alkoxy, hydroxyl, halogen, trifluoromethyl, nitro, methylenedioxy, ethylenedioxy, hydroxycarbonyl, (C_1-C_4) -alkoxycarbonyl, aminocarbonyl, cyano, phenyl, phenoxy, benzyl and benzyloxy, a pyridyl radical, a (C_1-C_4) -alkyl radical, a (C_2-C_4) -alkynyl radical or a (C_5-C_6) -cycloalkyl radical;

 R^{10} is hydroxyl or (C_1-C_8) -alk xy;

 R^{13} is (C_1-C_6) -alkyl, (C_3-C_7) -c/ycloalkyl or benzyl;

b, c and d are 1 and e and g are/C;

h is 1 or 2; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

51. The method as/claimed in claim 21, wherein

A is ethylene, trimethylene, tetramethylene, pentamethylene, cyclohexylene, phenylene, phenylene, phenylene, phenylene, tetramethylene, cyclohexylene, phenylene, phe

B is an unsubstituted or substituted methylene radical or ethylene radical;

D is $C(R^2)(R^3)$;

R is hydrogen of (C_1-C_4) -alkyl;

is (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl (C_1-C_8) -alkyl, optionally substituted in the aryl radical;

R¹ is $H_2N-C(=NH)$, $H_2N-C(=NH)-NH$ or H_2N-CH_2 ;

-28-

F&L POTOMAC

(៥) បបម

Mes

Serial No. 08/971,960

R² is hydrogen;

 R^3 is $R^{11}NH$;

 R^{10} is hydroxyl or (C_1-C_8) -alkoxy;

 R^{13} is (C_1-C_6) -alkyl, (C_3-C_7) -c;/cloalkyl or benzyl;

b, c, d and e are 1 and g is 0;

h is 0; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

- 52. The method as claimed in claim 21 in which a substituted methylene radical or substituted ethylene radical representing the group B carries as a substituent a radical selected from the group consisting of (C_1-C_8) -alkyl, (C_2-C_6) -alkenyl, (C_2-C_6) -alkynyl, (C_3-C_8) -cycloalkyl, (C_3-C_8) -cycloalkyl- (C_3-C_4) -alkyl, optionally substituted (C_6-C_{10}) -aryl- (C_1-C_4) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl and heteroaryl- (C_1-C_4) -alkyl; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.
- 53. The method as claimed in claim 21, in which B is an unsubstituted methylene radical or a methylene radical which is substituted by a (C₁-C₈)-alkyl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.
- 54. The method as claimed in claim 21, in which B is an unsubstituted methylene radical or a methylene radical which is substituted by a (C₁-C₆)-alkyl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

55. The method as claimed in claim 22, wherein

is a bivalent radical from the group consisting of (C_1-C_6) -alkylene, (C_3-C_7) -cycloalkylene, phenylene- (C_1-C_6) -alkyl, (C_1-C_6) -alkylenephenyl, phenylene- (C_2-C_6) -alkenyl or a bivalent radical of a 5- or 6-membered saturated or unsaturated ring which can contain 1 or 2 nitrogen atoms and can be mono- or disubstituted by (C_1-C_6) -alkyl or doubly bonde 1 oxygen or sulfur;

- is a bivalent radical from the group consisting of (C_1-C_6) -alkylene, (C_2-C_6) -alkenylene, phenylene, phenylene- (C_1-C_3) -alkylene-phenyl;
- D is $C(R^2)(R^3)$, $N(R^3)$ or $CH = C(R^3)$;
- R and R⁰ independently of one another are hydrogen, (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical;
- R¹ is X-NH-C(=NH)-(CH₂)_p ϕ r X¹-NH-(CH₂)_p, where p is 0, 1, 2 or 3;
- is hydrogen, (C_1-C_6) -alkyl, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_6) -alkoxycarbonyl, optionally substituted (C_6-C_{14}) -arylcarbonyl, optionally substituted (C_6-C_{14}) -aryloxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl which can also be substituted in the aryl radical, $(R^8O)_2P(O)$, cyano, hydroxyl, (C_1-C_6) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxy which can also be substituted in the aryl radical, or amino;
- X^1 has one of the meanings of X or is R'-NH-C(=N-R') where R' and R'' independently of one another have the meanings of X;
- is hydrogen, (C_1/C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally/substituted in the aryl radical or (C_3-C_8) -cycloalkyl;
- is hydrogen, (C_1 - C_8)-alkyl, optionally substituted (C_6 - C_{14})-aryl, (C_6 - C_{14})-aryl-(C_1 - C_8)-alkyl, optionally substituted in the aryl radical, (C_3 - C_8)-cycloalkyl, (C_2 - C_8)-alkenyl, (C_2 - C_8)-alkynyl, (C_2 - C_8)-alkynyl, (C_2 - C_8)-alkynylcarbonyl, pyridyl, $R^{11}NH$, R^4CO , $COOR^4$, $CON(CH_3)R^{14}$, $CONHR^{14}$, $CSNHR^{14}$, $COOR^{15}$, $CON(CH_3)R^{15}$ or $CONHR^{15}$;

R⁴ is hydrogen or (C₁-C₂₈)-alleyl which can optionally be mono- or polysubstituted by identical or different radicals R⁴;

R⁴' is hydroxyl, hydroxycarb(nyl, aminocarbonyl, mono- or di-((C_1 - C_{18})-alkylaminocarbonyl, amino-(C_1 - C_3)-alkylaminocarbonyl, amino-(C_1 - C_3)-alkylaminocarbonyl, (C_1 - C_1)-alkoxycarbonyl which can also be substituted in the aryl radical, amino, mercapto, (C_1 - C_1)-alkoxy, (C_1 - C_1)-alkoxycarbonyl, optionally substituted (C_3 - C_8)-cycloalkyl, halogen, nitro, trifluoromethyl or the radical R^5 ;

is optionally substituted (C_6 - C_{14})-aryl-(C_6 - C_{14})-aryl-(C_1 - C_8)-alkyl optionally substituted in the aryl radical, a mono- or bicyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated or completely hydrogenated and which can contain one, two or three identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur, a radical R^6 or a radical R^0 CO-, where the aryl radical and, independently thereof, the heterocyclic radial can be mono- or polysubstituted by identical or different radicals from the group consisting of (C_1 - C_{18})-alkyl, (C_1 - C_{18})-alkoxy, halogen, nitro, amino or trifluoromethyl,

is R^7R^8N , R^7O or R^7S or an amino acid side chain, a natural or unnatural amino acid, imino acid, optionally $N-(C_1-C_8)-n$ kylated or $N-((C_6-C_{14})-aryl-(C_1-C_8)-a$ kylated) azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to $-NF-CH_2$, and their esters and amides, where hydrogen or hydroxymethyl can optionally stand in place of free functional groups and/or where free functional groups can be protected by protective groups customary in peptide chemistry;

is hydrogen, (C_1-C_{18}) -alkyl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl, (C_1-C_{18}) -alkylcarbonyl, (C_1-C_{18}) -alkylcarbonyl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkylcarbonyl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkylcarbonyl or (C_6-C_{14}) -aryl- (C_1-C_{18}) -alkyloxycarbonyl, where the alkyl groups can optionally be substituted by an amino group and/or where the aryl radicals can be mono-or polysubstituted by identical or different radicals from the group consisting of (C_1-C_8) -alkyl, (C_1-C_8) -alkoxy, halogen, nitro, amino and trifluoromethyl, or is a natural or unnatural amino acid, imino acid, optionally N- (C_1-C_8) -alkylated or N- $((C_6-C_{14})$ -aryl (C_1-C_8) -alkylated) azaamino acid or a dipeptide radical

which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to -NH-CH₂-;

R⁸ is hydrogen, $(C_1 C_{18})$ -alkyl, optionally substituted $(C_6 - C_{14})$ -aryl or $(C_6 - C_{14})$ -aryl- $(C_1 - C_8)$ -alkyl which can also be substituted in the aryl radical;

R° is hydrogen, aminocarbonyl, (C_1-C_{18}) -alkylaminocarbonyl, (C_3-C_8) -cycloalkylaminocarbonyl, optionally substituted (C_6-C_{14}) -arylaminocarbonyl, (C_1-C_{18}) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_3-C_8) -cycloalkyl;

R¹⁰ is hydroxyl, (C_1-C_{18}) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;

is hydrogen, (C_1-C_{18}) -alkyl, $R^{12}CO$, optionally substituted (C_6-C_{14}) -aryl- $S(O)_2$, (C_1-C_{18}) -alkyl- $S(O)_2$, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or $R^9NHS(O)_2$; is hydrogen, (C_1-C_{18}) -alkyl, (C_2-C_8) -alkenyl, (C_2-C_8) -alkynyl, optionally substituted (C_6-C_{14}) -aryl, (C_1-C_{18}) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;

R¹³ is hydrogen, (C_1-C_6) -alkyl (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or (C_3-C_8) -cycloalkyl;

is hydrogen or (C_1-C_{28}) -alltyl which can optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxyl, hydroxycarbonyl, amino-carbonyl, mono- or di- $((C_1-C_{18})$ -alkyl)aminocarbonyl, amino- (C_2-C_{18}) -alkylaminocarbonyl, amino- (C_1-C_3) -alkylphenyl- (C_1-C_8) -alkylaminocarbonyl, (C_1-C_{18}) -alkylcarbonylamino- (C_1-C_3) -alkyl henyl- (C_1-C_3) -alkylaminocarbonyl, (C_1-C_{18}) -alkylcarbonylamino- (C_2-C_{18}) -alkylaminocarbonyl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxycarbonyl which can also be substituted in the aryl radical, amino, mercapto, (C_1-C_{18}) -alkoxy, (C_1-C_{18}) -alkoxycarbonyl, optionally substituted (C_3-C_8) -cycloalkyl, (C_1-C_3) -alkyl, (C_1-C_3) -alkyl, halogen, nitro, trifluoromethyl and (C_1-C_3) -alkyl, tetrazolyl- (C_1-C_3) -alkyl, halogen, nitro,

图 0 I 2

Serial No. 08/971,960

 R^{15} is R^{16} -(C_1 - C_6)-alkyl or R^{16} .

R¹⁶ is a 6- to 24-membered bicyclic or tricyclic radical which is saturated or partially unsaturated and which can also contain one to four identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur and which can also be substituted by one or more identical or different substituents from the group consisting of (C₁-C₄)-alkyl and oxo; b, c, and d independently of one another are 0 or 1, but cannot all simultaneously be 0; e, g and h independently of one another are 0, 1, 2, 3, 4, 5 or 6; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

- 56. The method as claimed in claim 22, wherein R^0 is (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, (C_3-C_8) -cycloalkyl- (C_1-C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.
- 57. The method as claimed in claim 56, wherein R⁰ is biphenylylmethyl, naphthylmethyl or benzyl each of which is unsubstituted or monosubstituted or polysubstituted in the aryl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.
 - 58. The method as claimed in claim 22, wherein

is a bivalent radical from the group consisting of methylene, ethylene, trimethylene, tetramethylene, vinylene, phenylene, or is substituted methylene or ethylene;

R is hydrogen, (C_1/C_6) -alkyl or benzyl;

R⁰ is (C_1-C_8) -alkyl, (C_3-C_8) -c₁/c₁/oalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl optionally substituted in the aryl radical;

 R^1 is X-NH-C(=NH), X-NH-C(=NX)-NH or X-NH-CH₂;

x is hydrogen, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_8) -alkylcarbonyloxy- (C_1-C_6) -alkoxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl or hydroxyl;

 R^2 is hydrogen or (C_1-C_8) -alkyl;

is (C_1-C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, (C_2-C_8) -alkenyl, (C_2-C_8) -alkynyl, pyridyl, $R^{11}NH$, R^4CO , $COOR^4$, $CONHR^{14}$, $CSNHR^{14}$, $COOR^{16}$ and $CONHR^{15}$;

and e, g and h independently of one another are the numbers 0, 1, 2 or 3; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

- 59. The method as claimed in claim 22, wherein W is R^1 -A-C(R^{13}) and R^{13} is (C_1 - C_6)-alkyl, (C_6 - C_{14})-aryl-(C_1 - C_8)-alkyl optionally substituted in the aryl radical or (C_3 - C_8)-cycloalkyl; wherein said compound or compounds may be present in all their stereoisometric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.
- 60. The method as claimed in claim 22, wherein R^3 is optionally substituted (C_6-C_{14}) -aryl, $COOR^4$, $R^{11}NH$ or $CONHR^{14}$, where $-NHR^{14}$ is the radical of an α -amino acid, its α -amino- (C_2-C_8) -alkylamide, its (C_1-C_8) -alkyl ester or its (C_6-C_{14}) -aryl- (C_1-C_4) -alkyl ester; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.
- 61. The method as claimed in claim 60, wherein the radical of the α -amino acid is selected from the group consisting of valine, lysine, phenylglycine, phenylalanine, tryptophan, and their (C_1-C_8) -alkyl esters or (C_6-C_{14}) -alkyl esters; wherein said compound or compounds



may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable sal's.

62. The method as claimed in claim 22, wherein

 \mathbf{Z} is $\mathbf{N}(\mathbf{R}^0)$;

A is ethylene, trimethylene, tetramethylene, pentamethylene, cyclohexylene, phenylene or phenylenemethyl;

B is an unsubstituted or substituted methylene radical;

D is $C(\mathbb{R}^2)(\mathbb{R}^3)$;

R is hydrogen or (C_1-C_4) -alkyl;

is (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl-aryl-alkyl optionally substituted in the aryl radical;

R¹ is $H_2N-C(=NH)$, $H_2N-C(=NH)-NH$ or H_2N-CH_2 ;

R² is hydrogen:

R³ is the radical CONHR¹⁴;

 R^{10} is hydroxyl or (C/C_8) -alkoxy;

 R^{13} is (C_1-C_6) -alkyl, (C_3-C_7) -cycloalkyl or benzyl;

is methyl which is substituted by hydroxycarbonyl and a radical from the group consisting of (C_1-C_4) -alkyl, phenyl and benzyl, or is methyl which is substituted by (C_1-C_8) -alkoxycarbonyl and a radical from the group consisting of (C_1-C_4) -alkyl, phenyl and benzyl; b, c and d are 1 and/e and g are 0:

h is 1 or 2; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

F&L PUIUM

Serial No. 08/971,960

- 63. The method as claimed in claim 22, wherein simultaneously W is R¹-A-C(R¹³) and therein A is a bivalent radical selected from the group consisting of methylene, ethylene, trimethylene, tetramethylene, pentamethylene, cyclopexylene, phenylene phenylenemethyl;
- B is a bivalent radical from the group consisting of methylene, ethylene, trimethylene, tetramethylene, vinylene, phenylene or is substituted methylene or ethylene;
- R is hydrogen or (C_1-C_6) -alkyl;
- R° is (C_1-C_8) -alkyl, (C_3-C_8) -c/cloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl-aryl optionally substituted in the aryl radical;
- R^1 is X-NH-C(=NH), X-NH-C(=NX)-NH or X-NH-CH₂;
- X is hydrogen, (C_1-C_6) -alkyl arbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_8) -alkylcarbonyloxy- (C_1-C_6) -alkoxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl or hydroxyl;
- R^2 is hydrogen or (C_1-C_8) /alkyl;
- R³ is CONHR¹⁵ or CONHR¹⁴ where R¹⁴ herein is a (C_1-C_8) -alkyl radical which is unsubstituted or substituted by one or more (C_6-C_{14}) -aryl radicals;
- R^{15} is R^{16} -(C_1 - C_6)-alkyl or R^{16} , where R^{16} is a 7- to 12-membered bridged bicyclic or tricyclic radical which is saturated or partially unsaturated and which can also contain one to four identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur and which can also be substituted by one or more identical or different substituents from the group consisting of $(C_1$ - C_4)-alkyl and oxo;

and e, g and h/independently of one another are the numbers 0, 1, 2 or 3 and b, c and d are 1; wherein said/compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

64. The method as claimed in claim 63, wherein R¹⁵ is an adamantyl radical or an adamantylmethyl radical; whereir said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

65. The method as claimed in claim 22, wherein

is ethylene, trimethylene, tetramethylene, penramethylene, cyclohexylene, phenylenemethyl;

B is an unsubstituted or substituted methylene radical;

D is $C(\mathbb{R}^2)(\mathbb{R}^3)$;

R is hydrogen or (C_1-C_4) -alkyl;

R⁰ is (C_1-C_8) - alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical;

 R^1 is $H_2N-C(=NH)$, $H_2N-C(=NH)$ -NH or H_2N-CH_2 ;

R² is hydrogen;

R³ is CONHR¹⁵ or CONHR¹⁴ where R¹⁴ herein is a (C_1-C_6) -alkyl radical which is unsubstituted or substituted by one or more (C_6-C_{10}) -aryl radicals;

 R^{10} is hydroxyl or (C_1-C_8) -alkoxy;

 R^{13} is (C_1-C_6) -alkyl, (C_3-C_7) -cycloalkyl or benzyl;

R¹⁵ is an adamantyl radical or an adamantylmethyl radical;

b, c and d are 1 and e and/g are 0;

h is 1 or 2; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

66. The method as claimed in claim 22, wherein

A is ethylene, trimethylene, etramethylene, pentamethylene, cyclohexylene, phenylenemethyl;

B is an unsubstituted or substituted methylene radical or ethylene radical;

D is $C(R^2)(R^3)$;

R is hydrogen or (C₁-C₄)-alkyl;

is (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl-aryl which is optionally substituted in the aryl radical;

R¹ is $H_2N-C(=NH)$, $H_2N-C(=NH)-NH$ or H_2N-CH_2 ;

R² is hydrogen;

is an unsubstituted phenyl radical or naphthyl radical, a phenyl radical or naphthyl radical substituted by one, two or three identical or different radicals from the group consisting of (C_1-C_4) -alkyl, (C_1-C_4) -alkoxy, hydroxyl, halogen, trifluoromethyl, nitro, methylenedioxy, ethylenedioxy, hydroxycarbonyl, (C_1-C_4) -alkoxycarbonyl, aminocarbonyl, cyano, phenyl, phenoxy, benzyl and benzyloxy, pyridyl radical, a (C_1-C_4) -alkyl radical, a (C_2-C_4) -alkynyl radical or a (C_5-C_6) -cycloalkyl radical;

 R^{10} is hydroxyl or $(C_1 - C_8)$ -alkoxy;

 R^{13} is (C_1-C_6) -alkyl, (C_3-C_7) -c./cloalkyl or benzyl;

b, c and d are 1 and e and g are 0;

h is 1 or 2; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

67. The method as claimed in claim 22, wherein

A is ethylene, trimethylene, tetramethylene, pentamethylene, cyclohexylene, phenylene, phenylene, phenylene, phenylene, tetramethylene, cyclohexylene, phenylene, phe

B is an unsubstituted or substituted methylene radical or ethylene radical;

D is $C(R^2)(R^3)$;

R is hydrogen or (C_4-C_4) -alkyl;

R⁰ is (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -a

AL PUIUMAC

Mark

Serial No. 08/971,960

 R^1 is $H_2N-C(=NH)$, $H_2N-C(=NH)-NH$ or H_2N-CH_2 ;

R² is hydrogen;

 R^3 is $R^{11}NH$;

 R^{10} is hydroxyl or $(C_1 - C_8)$ -alkoxy;

 R^{13} is (C_1-C_6) -alkyl (C_3-C_7) -c/cloalkyl or benzyl;

b, c, d and e are 1 and g is 0;

h is 0; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

- 68. The method as claimed in claim 22 in which a substituted methylene radical or substituted ethylene radical representing the group B carries as a substituent a radical selected from the group consisting of (C_1-C_8) -alkyl, (C_2-C_6) -alkenyl, (C_2-C_6) -alkynyl, (C_3-C_8) -cycloalkyl, (C_3-C_8) -cycloalkyl- (C_3-C_4) -alkyl, optionally substituted (C_6-C_{10}) -aryl, (C_6-C_{10}) -aryl- (C_1-C_4) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl and heteroaryl- (C_1-C_4) -alkyl; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.
- 69. The method as claimed in claim 22, in which B is an unsubstituted methylene radical or a methylene radical which is substituted by a (C₁-C₈)-alkyl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.
- 70. The method as claimed in claim 22, in which B is an unsubstituted methylene radical or a methylene radical which is substituted by a (C_1-C_6) -alkyl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

71. The method as claimed in claim 23, wherein

A is a bivalent radical from the group consisting of (C_1-C_6) -alkylene, (C_3-C_7) -cycloalkylene, phenylene- (C_1-C_6) -alkyl, (C_1-C_6) -alkylenephenyl, phenylene- (C_2-C_6) -alkenyl or a bivalent radical of a 5- or 6-membered saturated or unsaturated ring which can contain 1 or 2 nitrogen atoms and can be mono- or disubstituted by (C_1-C_6) -alkyl or doubly bonded oxygen or sulfur;

B is a bivalent radical from the group consisting of (C_1-C_6) -alkylene, (C_2-C_6) -alkenylene, phenylene, phenylene, (C_1-C_3) -alkyl, (C_1-C_3) -alkylene-phenyl;

D is $C(R^2)(R^3)$, $N(R^3)$ or $CH = C(R^3)$;

R and R⁰ independently of one another are hydrogen, (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical;

R¹ is X-NH-C(=NH)-(CH₂)_p or X¹-NH-(CH₂)_p, where p is 0, 1, 2 or 3;

is hydrogen, (C_1-C_6) -alkyl, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_1) -alkoxycarbonyl, (C_1-C_6) -alkoxycarbonyl, optionally substituted (C_6-C_{14}) -arylcarbonyl, optionally substituted (C_6-C_{14}) -aryloxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl which can also be substituted in the aryl radical, $(R^8O)_2P(O)$, cyano, hydroxyl, (C_1-C_6) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxy which can also be substituted in the aryl radical, or amino;

has one of the meanings of X or is R'-NH-C(=N-R") where R' and R'' independently of one another have the meanings of X;

R² is hydrogen, (C_1-C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or (C_3-C_8) -cycloalkyl;

is hydrogen, (C_1-C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl, optionally substituted in the aryl radical, (C_3-C_8) -cycloalkyl, (C_2-C_8) -alkenyl, (C_2-C_8) -alkenyl, (C_2-C_8) -alkynyl, (C_2-C_8) -alkenylcarbonyl, pyridyl, (C_1-C_8) -alkynylcarbonyl, pyridyl, (C_1-C_8) -alkynylcarbonyl, pyridyl, (C_1-C_8) -alkynylcarbonyl, (C_1-C_8) -alkynylcarbonyl, pyridyl, (C_1-C_1) -alkynylcarbonyl, pyridyl, (C_1-C_1) -alkynylcarbonyl, pyridyl, (C_1-C_1) -alkynylcarbonyl, (C_1-C_1) -alkynylcarbonyl, pyridyl, (C_1-C_1) -alkynylcarbonyl, (C_1-C_1) -alkynylcarbonyl, pyridyl, (C_1-C_1) -alkynylcarbonyl, pyridyl, (C_1-C_1) -alkynylcarbonyl, (C_1-C_1) -alkynylcarbonyl, pyridyl, (C_1-C_1) -alkynylcarbonyl, (C_1-C_1) -alkynylcarbonyl, (C_1-C_2) -alkynylcarbonyl, pyridyl, (C_1-C_1) -alkynylcarbonyl, (C_1-C_2) -alkynylcarbonylcarbonyl, (C_1-C_2) -alkynylcarbonylcarbonylcarbonylcarbonylcarbonylcarbonylc

is hydrogen or (C₁-C₂₈)-alcyl which can optionally be mono- or polysubstituted by R⁴ identical or different radicals R4;

 R^4 is hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or di-((C1-C18)alkyl)aminocarbonyl, amino- (C_2-C_{18}) -alkylam/nocarbonyl, amino- (C_1-C_3) -alkylphenyl- (C_1-C_3) alkylaminocarbonyl, (C₁-C₁₈)-alkylcarbonylamino-(C₁-C₃)-alkylphenyl-(C₁-C₃)alkylaminocarbonyl, (C_1-C_{18}) -alkylamino- (C_2-C_{18}) -alkylaminocarbonyl, (C_6-C_{14}) -aryl-(C₁-C₈)-alkoxycarbonyl which can also be substituted in the aryl radical, amino, mercapto, (C₁-C₁₈)-alkoxy, (C₁-C₁₈)-alkoxycarbonyl, optionally substituted (C₃-C₈)-cycloalkyl, halogen, nitro, trifluoromethyl or the radical R⁵;

is optionally substituted (C_6-C_1)-aryl, (C_6-C_{14})-aryl-(C_1-C_8)-alkyl optionally substituted in the aryl radical, a mono- or bicyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated or completely hydrogenated and which can contain one, two or three identical or different heter datoms from the group consisting of nitrogen, oxygen and sulfur, a radical R⁶ or a radical R⁶CO-, where the aryl radical and, independently thereof, the heterocyclic radial can be mono- or polysubstituted by identical or different radicals from the group consisting of (C₁-C₁₈)-alky/l, (C₁-C₁₈)-alkoxy, halogen, nitro, amino or trifluoromethyl;

is R⁷R⁸N, R⁷O or R⁷S of an amino acid side chain, a natural or unnatural amino acid, R^6 imino acid, optionally $N-(C_1-Q_8)$ -alkylated or $N-((C_6-C_{14})-aryl-(C_1-C_8)-alkylated)$ azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced/to -NH-CH2-, and their esters and amides, where hydrogen or hydroxymethyl can optionally stand in place of free functional groups and/or where free functional groups can be protected by protective groups customary in peptide chemistry;

 \mathbb{R}^7 is hydrogen, (C_1-Q_{18}) -alkyl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl, (C_1-C_{18}) -alkylcarbonyl, (C_1-C_{18}) -alkylc C_{18})-alkoxycarbonyl, (C_6/C_{14}) -ary|carbonyl, (C_6-C_{14}) -ary|-(C_1-C_8)-alky|carbonyl or (C_6-C_{14}) aryl-(C₁-C₁₈)-alkyloxycarbonyl, where the alkyl groups can optionally be substituted by an amino group and/or where the aryl radicals can be mono-or polysubstituted by identical or different radicals from the group consisting of (C1-C2)-alkyl, (C1-C2)-alkoxy, halogen, nitro, amino and trifluoromethyl, or is a natural or unnatural amino acid, imino acid, optionally N- (C_1-C_8) -alkylated or $N-((C_6-C_{14})$ -aryl (C_1-C_8) -alkylated) azaamino acid or a dipeptide radical

0/14/88 INC 22.21 IAA 0381

IGE TOTOMIC

Serial No. 08/971,960

which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to -NH-CH₂-;

R⁸ is hydrogen, (C_1-C_{18}) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl which can also be substituted in the aryl radical;

R⁹ is hydrogen, aminocarbonyl, (C_1-C_{18}) -alkylaminocarbonyl, (C_3-C_8) -cycloalkylaminocarbonyl, optionally substituted (C_6-C_{14}) -arylaminocarbonyl, (C_1-C_{18}) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_3-C_8) -cycloalkyl;

R¹⁰ is hydroxyl, (C_1-C_{18}) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;

R¹¹ is hydrogen, (C_1-C_{18}) -alkyl, $R^{12}CO$, optionally substituted (C_6-C_{14}) -aryl- $S(O)_2$, (C_1-C_{18}) -alkyl- $S(O)_2$, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or $R^9NHS(O)_2$; R^{12} is hydrogen, (C_1-C_{18}) -alkyl, (C_2-C_8) -alkenyl, (C_2-C_8) -alkynyl, optionally substituted (C_6-C_{14}) -aryl, (C_1-C_{18}) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;

R¹³ is hydrogen, $(C_1 - C_6)$ -alkyl, $(C_6 - C_{14})$ -aryl- $(C_1 - C_8)$ -alkyl optionally substituted in the aryl radical or $(C_3 - C_8)$ -cycloalkyl;

is hydrogen or (C_1-C_{28}) -allyl which can optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxyl, hydroxycarbonyl, amino-carbonyl, mono- or di- $((C_1-C_{18})$ -alkyl)aminocarbonyl, amino- (C_2-C_{18}) -alkylaminocarbonyl, amino- (C_1-C_3) -alkylphenyl- (C_1-C_8) -alkylaminocarbonyl, (C_1-C_{18}) -alkylcarbonylamino- (C_1-C_3) -alkylphenyl- (C_1-C_3) -alkylaminocarbonyl, (C_1-C_{18}) -alkylcarbonylamino- (C_2-C_{18}) -alkylaminocarbonyl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxycarbonyl which can also be substituted in the aryl radical, amino, mercapto, (C_1-C_1) -alkoxy, (C_1-C_{18}) -alkoxycarbonyl, optionally substituted (C_3-C_8) -cycloalkyl, (C_1-C_3) -alkyl, (C_1-C_3) -alkyl, halogen, nitro, trifluoromethyl and (C_1-C_3) -alkyl, tetrazolyl- (C_1-C_3) -alkyl, halogen, nitro,

IGE TOTOMA

-E-0-E-0

Serial No. 08/971,960

 R^{15} is R^{16} -(C_1 - C_6)-alkyl or R^{16} .

 R^{16} is a 6- to 24-membered bicyclic or tricyclic radical which is saturated or partially unsaturated and which can also contain one to four identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur and which can also be substituted by one or more identical or different substituents from the group consisting of (C_1-C_4) -alkyl and oxo;

b, c, and d independently of one another are 0 or 1, but cannot all simultaneously be 0; e, g and h independently of one another are 0, 1, 2, 3, 4, 5 or 6; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 23, wherein R^0 is (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, (C_3-C_8) -cycloalkyl- (C_4-C_4) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 73, wherein R⁰ is biphenylylmethyl, naphthylmethyl or benzyl each of which is unsubstituted or monosubstituted or polysubstituted in the aryl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

7\$\frac{1}{4}\$ The method as/claimed in claim 23, wherein

B is a bivalent radical from the group consisting of methylene, ethylene, trimethylene, tetramethylene, vinylene, phenylene, or is substituted methylene or ethylene;

R is hydrogen, (Q_1-C_6) -alkyl or benzyl;

- is a bivalent radical from the group consisting of (C_1-C_6) -alkylene, (C_2-C_6) -alkenylene, phenylene, phenylene- (C_1-C_3) -alkyl, (C_1-C_3) -alkylene-phenyl;
- D is $C(R^2)(R^3)$, $N(R^3)$ or $CH = C(R^3)$;
- R and R⁰ independently of one another are hydrogen, (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl of (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical;
- R¹ is X-NH-C(=NH)-(CH₂)_p or X¹-NH-(CH₂)_p, where p is 0, 1, 2 or 3;
 - is hydrogen, (C_1-C_6) -alkyl, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_1) -alkoxycarbonyl, optionally substituted (C_6-C_{14}) -arylcarbonyl, optionally substituted (C_6-C_{14}) -arylcarbonyl, optionally substituted (C_6-C_{14}) -aryloxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl which can also be substituted in the aryl radical, $(R^8O)_2P(O)$, cyano, hydroxyl, (C_1-C_6) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxy which can also be substituted in the aryl radical, or amino;
- has one of the meanings of X or is R'-NH-C(=N-R'') where R' and R'' independently of one another have the meanings of X;
- is hydrogen, (C_1-C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or (C_7-C_8) -cycloalkyl;
- is hydrogen, (C₁-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl, optionally substituted in the aryl radical, (C₃-C₈)-cycloalkyl, (C₂-C₈)-alkenyl, (C₂-C₈)-alkynyl, (C₂-C₈)-alkynylcarbonyl, pyridyl, R¹¹NH, R⁴CO, COOR⁴, CON(CII₃)R¹⁴, CONHR¹⁴, CSNHR¹⁴, COOR¹⁵, CON(CH₃)R¹⁵ or CONHR¹⁵;
- R⁴ is hydrogen or (C_1/C_{28}) -allyl which can optionally be mono- or polysubstituted by identical or different radicals R⁴;
- R⁴' is hydroxyl, hydroxycarbcnyl, aminocarbonyl, mono- or di-((C_1 - C_{18})-alkylaminocarbonyl, amino-(C_2 - C_{18})-alkylaminocarbonyl, amino-(C_1 - C_3)-alkylaminocarbonyl, (C_1 - C_{18})-alkylaminocarbonyl, (C_2 - C_{18})-alkylaminocarbonyl, (C_3 - C_{18})-alkylaminocarbonyl, (C_4 - C_{18})-alkylaminocarbonyl, (C_6 - C_{14})-aryl-

OF 147 00 INC BEIER IMM COOL

Serial No. 08/971,960

R⁰ is (C_1-C_8) -alkyl, (C_3-C_8) -c/cloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl-aryl optionally substituted in the aryl radical;

 R^1 is X-NH-C(=NH), X-NH-C(\neq NX)-NH or X-NH-CH₂;

is hydrogen, (C_1-C_6) -alkyl arbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl or hydroxyl;

 R^2 is hydrogen or (C_1-C_2) -alkyl;

R³ is (C_1-C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, (C_2-C_8) -alkenyl, (C_2-C_8) -alkynyl, pyridyl, R¹¹NH, R⁴CO, COOR⁴, CONHR¹⁴, CSNHR¹⁴, COOR¹⁵ and CONHR¹⁵;

and e, g and h independently of one another are the numbers 0, 1, 2 or 3; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

75. The method as claimed in claim 23, wherein W is R^1 -A-C(R^{13}) and R^{13} is (C_1 - C_6)-alkyl, (C_6 - C_{14})-aryl-(C_1 - C_8)-alkyl optionally substituted in the aryl radical or (C_3 - C_8)-cycloalkyl; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 23, wherein R^3 is optionally substituted (C_6 - C_{14})-aryl, COOR⁴, R^{11} NH or CONHR ⁴, where -NHR¹⁴ is the radical of an α -amino acid, its α -amino-(C_2 - C_8)-alkylamide, its (C_1 - C_8)-alkyl ester or its (C_6 - C_{14})-aryl-(C_1 - C_4)-alkyl ester; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 77, wherein the radical of the α -amino acid is selected from the group consisting of value, lysine, phenylglycine, phenylalanine, tryptophan, and their (C_1-C_8) -alkyl esters or (C_6-C_{14}) -alkyl esters; wherein said compound or compounds

may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

79. The method as claimed in claim 23, wherein

 \mathbb{Z} is $N(\mathbb{R}^0)$;

A is ethylene, trimethylene, tetramethylene, pentamethylene, cyclohexylene, phenylene or phenylenemethyl;

B is an unsubstituted or substituted methylene radical;

D is $C(R^2)(R^3)$;

R is hydrogen or (C_1-C_4) -alky),

R° is (C_1-C_8) -alkyl, (C_3-C_8) -c/cloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl-aryl-alkyl optionally substituted in the aryl radical;

 R^1 is $H_2N-C(=NH)$, $H_2N-C(:=NH)-NH$ or H_2N-CH_2 ;

R² is hydrogen;

R³ is the radical CONHR¹⁴;

 R^{10} is hydroxyl or $(C_{\downarrow}C_{g})$ -alkoxy;

 R^{13} is (C_1-C_6) -alkyl, $/(C_3-C_7)$ -cycloalkyl or benzyl;

is methyl which is substituted by hydroxycarbonyl and a radical from the group consisting of (C_1-C_4) alkyl, phenyl and benzyl, or is methyl which is substituted by (C_1-C_8) -alkoxycarbonyl and a radical from the group consisting of (C_1-C_4) -alkyl, phenyl and benzyl; b, c and d are l and e and g are 0;

h is 1 or 2; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

de

Serial No. 08/971,960

The method as claimed in claim 23, wherein simultaneously W is R^1 -A-C(R^{13}) and therein A is a bivalent radical selected from the group consisting of methylene, ethylene, trimethylene, tetramethylene, per tamethylene, cyclohexylene, phenylene, phenylenemethyl;

B is a bivalent radical from the group consisting of methylene, ethylene, trimethylene, tetramethylene, vinylene, phenylene or is substituted methylene or ethylene;

R is hydrogen or (C_1-C_6) -alkyl;

is (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl-aryl optionally substituted in the aryl radical;

R¹ is X-NH-C(=NH), X-NH-C(\neq NX)-NH or X-NH-CH₂;

X is hydrogen, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl or hydroxyl;

 R^2 is hydrogen or (C_1-C_8) -allyl;

R³ is CONHR¹⁵ or CONHR¹⁴ where R¹⁴ herein is a (C_1-C_8) -alkyl radical which is unsubstituted or substituted by one or more (C_6-C_{14}) -aryl radicals;

 R^{15} is R^{16} -(C_1 - C_6)-alkyl or R^{16} , where R^{16} is a 7- to 12-membered bridged bicyclic or tricyclic radical which is saturated or partially unsaturated and which can also contain one to four identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur and which can also be substituted by one or more identical or different substituents from the group consisting of $(C_1$ - C_4)-alkyl and oxo;

and e, g and h independently of one another are the numbers 0, 1, 2 or 3 and b, c and d are 1; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

80 The method as claimed in claim 80, wherein R¹⁵ is an adamantyl radical or an adamantylmethyl radical; whereir said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

8. The method as claimed in claim 23, wherein

is ethylene, trimethylene, etramethylene, pentamethylene, cyclohexylene, phenylene or phenylenemethyl;

B is an unsubstituted or substituted methylene radical;

D is $C(R^2)(R^3)$;

R is hydrogen or (C_1-C_4) -alkyl;

R⁰ is (C_1-C_8) - alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical;

 R^1 is $H_2N-C(=NH)$, $H_2N-C(:=NH)-NH$ or H_2N-CH_2 ;

R² is hydrogen;

R³ is CONHR¹⁵ or CONHR¹⁴ where R¹⁴ herein is a (C_1-C_6) -alkyl radical which is unsubstituted or substituted by one-or more (C_6-C_{10}) -aryl radicals;

 R^{10} is hydroxyl or (C_1-C_8) -alk(xy);

 R^{13} is (C_1-C_6) -alkyl, (C_3-C_7) -crcloalkyl or benzyl;

R¹⁵ is an adamantyl radical or an adamantylmethyl radical;

b, c and d are I and e and g are 0;

h is 1 or 2; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

83. The method as/claimed in claim 23, wherein

A is ethylene, trimethylene, etramethylene, pentamethylene, cyclohexylene, phenylene, phenylene, phenylene, phenylene, phenylene, cyclohexylene, phenylene, phenylene

B is an unsubstituted or substituted methylene radical or ethylene radical;

D is $C(R^2)(R^3)$;

R is hydrogen or (C_1-C_4) -alkyl;

is (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl-aryl-aryl-alkyl which is optionally substituted in the aryl radical;

 R^1 is $H_2N-C(=NH)$, $H_2N-C(=NH)$ -NH or H_2N-CH_2 ;

R² is hydrogen;

is an unsubstituted phenyl radical or naphthyl radical, a phenyl radical or naphthyl radical substituted by one, two or three identical or different radicals from the group consisting of (C_1-C_4) -alkyl, (C_1-C_4) -alkoxy, hydroxyl, halogen, trifluoromethyl, nitro, methylenedioxy, ethylenedioxy, hydroxycarbonyl, (C_1-C_4) -alkoxycarbonyl, aminocarbonyl, cyano, phenyl, phenoxy, benzyl and benzyloxy, a pyridyl radical, a (C_1-C_4) -alkyl radical, a (C_2-C_4) -alkynyl radical or a (C_5-C_6) -cycloalkyl radical;

 R^{10} is hydroxyl or (C_1-C_8) -alk xy;

 R^{13} is (C_1-C_6) -alkyl, (C_3-C_7) -q/cloalkyl or benzyl;

b, c and d are 1 and e and g are β ;

h is 1 or 2; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

83. The method as claimed in claim 23, wherein

A is ethylene, trimethylene, tetramethylene, pentamethylene, cyclohexylene, phenylene, phenylene phenylene phenylene phenylene.

B is an unsubstituted or substituted methylene radical or ethylene radical;

D is $C(\mathbb{R}^2)(\mathbb{R}^3)$;

R is hydrogen or (C_1-C_4) -alkyl;

R⁰ is (C_1-C_8) -alkyl, (C_3-C_8) -c./cloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl (C_1-C_8) -alkyl, optionally substituted in the aryl radical;



 R^1 is $H_2N-C(=NH)$, $H_2N-C(=NH)-NH$ or H_2N-CH_2 ;

R² is hydrogen;

 R^3 is $R^{11}NH$;

 R^{10} is hydroxyl or (C_1-C_8) -alkoxy;

 R^{13} is (C_1-C_6) -alkyl, (C_3-C_7) -cycloalkyl or benzyl;

b, c, d and e are/1 and g is 0;

h is 0; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 23 in which a substituted methylene radical or substituted ethylene radical representing the group B carries as a substituent a radical selected from the group consisting of (C_1-C_8) -alkyl, (C_2-C_6) -alkenyl, (C_2-C_6) -alkynyl, (C_3-C_8) -cycloalkyl, (C_3-C_8) -cycloalkyl- (C_3-C_4) -alkyl, optionally substituted (C_6-C_{10}) -aryl, (C_6-C_{10}) -aryl- (C_1-C_4) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl and heteroaryl- (C_1-C_4) -alkyl; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 23, in which B is an unsubstituted methylene radical or a methylene radical which is substituted by a (C₁-C₈)-alkyl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 23, in which B is an unsubstituted methylene radical or a methylene radical valich is substituted by a (C_1-C_6) -alkyl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

87. The method as claimed in claim 24, wherein

A is a bivalent radical from the group consisting of (C_1-C_6) -alkylene, (C_3-C_7) cycloalkylene, phenylene, phenylene- (C_1-C_6) -alkyl, (C_1-C_6) -alkylenephenyl, phenylene- (C_2-C_6) alkenyl or a bivalent radical of a 5- or 6-membered saturated or unsaturated ring which can
contain 1 or 2 nitrogen atoms and can be mono- or disubstituted by (C_1-C_6) -alkyl or doubly
bonded oxygen or sulfur;

B is a bivalent radical from the group consisting of (C_1-C_6) -alkylene, (C_2-C_6) -alkenylene, phenylene, phenylene- (C_1-C_3) -alkyl, (C_1-C_3) -alkylene-phenyl;

D is $C(R^2)(R^3)$, $N(R^3)$ or $CH = C(R^3)$;

R and R⁰ independently of one another are hydrogen, (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical;

R¹ is X-NH-C(=NH)-(CH₂)_p or X^1 -NH-(CH₂)_p, where p is 0, 1, 2 or 3;

is hydrogen, (C_1-C_6) -alkyl, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_{18}) -alkylcarbonyloxy- (C_1-C_6) -alkoxycarbonyl, optionally substituted (C_6-C_{14}) -arylcarbonyl, optionally substituted (C_6-C_{14}) -arylcarbonyl which can also be substituted in the aryl radical, $(R^8O)_2P(O)$, cyano, hydroxyl, (C_1-C_6) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxy which can also be substituted in the aryl radical, or amino;

 X^1 has one of the meanings of X or is R'-NH-C(=N-R") where R' and R'' independently of one another have the meanings of X;

R² is hydrogen, (C_1-C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or (C_3-C_8) -cycloalkyl;

is hydrogen, (C/-C₈)-alkyl, optionally substituted (C₆-C₁₄)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl, optionally substituted in the aryl radical, (C₃-C₈)-cycloalkyl, (C₂-C₈)-alkenyl, (C₂-C₈)-alkynyl, (C₂-C₈)-alkynylcarbonyl, pyridyl, R¹¹NH, R⁴CO, COOR⁴, CON(CH₃)R¹⁴, CONHR¹⁴, CSNHR¹⁴, COOR¹⁵, CON(CH₃)R¹⁵ or CONHR¹⁵;

 R^4 is hydrogen or (C_1-C_{28}) -all yl which can optionally be mono- or polysubstituted by identical or different radicals R^4 ;

R⁴' is hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or di-((C_1 - C_{18})-alkylaminocarbonyl, amino-(C_2 - C_{18})-alkylaminocarbonyl, amino-(C_1 - C_3)-alkylaminocarbonyl, (C_1 - C_{18})-alkylaminocarbonyl, (C_1 - C_1)-alkylaminocarbonyl, (C_1 - C_1)-alkoxycarbonyl which car also be substituted in the aryl radical, amino, mercapto, (C_1 - C_1)-alkoxy, (C_1 - C_1)-alkoxycarbonyl, optionally substituted (C_3 - C_8)-cycloalkyl, halogen, nitro, trifluoromethyl or the radical R⁵;

is optionally substituted (C_6 - C_{4})-aryl, (C_6 - C_{14})-aryl-(C_1 - C_8)-alkyl optionally substituted in the aryl radical, a mono- or bicyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated or completely hydrogenated and which can contain one, two or three identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur, a radical R^6 or a radical R^6 -CO-, where the aryl radical and, independently thereof, the heterocyclic radial can be mono- or polysubstituted by identical or different radicals from the group consisting of (C_1 - C_{18})-alkyl, (C_1 - C_{18})-alkoxy, halogen, nitro, amino or trifluoromethyl;

is R^7R^8N , R^7O or R^7S of an amino acid side chain, a natural or unnatural amino acid, imino acid, optionally $N-(C_1-C_8)-ilkylated$ or $N-((C_6-C_{14})-aryl-(C_1-C_8)-alkylated)$ azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to $-NH-CH_2-$, and their esters and amides, where hydrogen or hydroxymethyl can optionally stand in place of free functional groups and/or where free functional groups can be protected by protective groups customary in peptide chemistry;

is hydrogen, (C_1-C_{18}) -alkyl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl, (C_1-C_{18}) -alkylcarbonyl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkylcarbonyl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkylcarbonyl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyloxycarbonyl, where the alkyl groups can optionally be substituted by an amino group and/or where the aryl radicals can be mono-or polysubstituted by identical or different radicals from the group consisting of (C_1-C_8) -alkyl, (C_1-C_8) -alkoxy, halogen, nitro, amino and trifluoromethyl, or is a natural or unnatural amino acid, imino acid, optionally N- (C_1-C_8) -alkylated or N- $((C_6-C_{14})$ -aryl (C_1-C_8) -alkylated) azaamino acid or a dipeptide radical

which can also be substituted in the aryl radical and/or in which the peptide bond can be reduced to -NH-CH₂-;

R⁸ is hydrogen, (C_1-C_{18}) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl which can also be substituted in the aryl radical;

R° is hydrogen, aminocarbonyl, (C_1-C_{18}) -alkylaminocarbonyl, (C_3-C_8) -cycloalkylaminocarbonyl, optionally substituted (C_6-C_{14}) -arylaminocarbonyl, (C_1-C_{18}) -alkyl, optionally substituted (C_6-C_{14}) -aryl or (C_3-C_8) -cycloalkyl;

R¹⁰ is hydroxyl, (C_1-C_{18}) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;

R¹¹ is hydrogen, (C_1-C_{18}) -alkyl, $R^{12}CO$, optionally substituted (C_6-C_{14}) -aryl- $S(O)_2$, (C_1-C_{18}) -alkyl- $S(O)_2$, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or $R^9NHS(O)_2$; R¹² is hydrogen, (C_1-C_{18}) -alkyl, (C_2-C_8) -alkenyl, (C_2-C_8) -alkynyl, optionally substituted (C_6-C_{14}) -alkyl)

 C_{14})-aryl, (C_1-C_{18}) -alkoxy, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14}) -aryloxy, amino or mono- or di- $((C_1-C_{18})$ -alkyl)amino;

R¹³ is hydrogen, (C_1-C_6) -alkyl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical or (C_3-C_8) -cycloalkyl;

is hydrogen or (C_1-C_{2R}) -allcyl which can optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxyl, hydroxycarbonyl, amino-carbonyl, mono- or di- $((C_1\cdot C_{1R})$ -alkyl)aminocarbonyl, amino- (C_2-C_{1R}) -alkylaminocarbonyl, amino- (C_1-C_3) -alkylphenyl- (C_1-C_8) -alkylaminocarbonyl, (C_1-C_{1R}) -alkylcarbonylamino- (C_1-C_3) -alkyl phenyl- (C_1-C_3) -alkylaminocarbonyl, (C_1-C_{1R}) -alkylcarbonylamino- (C_2-C_{1R}) -alkylaminocarbonyl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkoxycarbonyl which can also be substituted in the aryl radical, amino, mercapto, (C_1-C_{1R}) -alkoxy, (C_1-C_{1R}) -alkoxycarbonyl, optionally substituted (C_3-C_8) -cycloalkyl, (C_1-C_3) -alkyl, (C_1-C_3) -alkyl, (C_1-C_3) -alkyl, (C_1-C_3) -alkyl, (C_1-C_3) -alkyl, tetrazolyl- (C_1-C_3) -alkyl, halogen, nitro, trifluoromethyl and (C_3-C_3) -alkyl, tetrazolyl- (C_1-C_3) -alkyl, halogen, nitro,

 R^{15} is R^{16} -(C_1 - C_6)-alkyl or R^{16} ;

R¹⁶ is a 6- to 24-membered bicyclic or tricyclic radical which is saturated or partially unsaturated and which can also contain one to four identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur and which can also be substituted by one or more identical or different substituents from the group consisting of (C₁-C₄)-alkyl and oxo;

b, c, and d independently of one another are 0 or 1, but cannot all simultaneously be 0; e, g and h independently of one another are 0, 1, 2, 3, 4, 5 or 6; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

88. The method as claimed in claim 24, wherein R^0 is (C_1-C_8) -alkyl, (C_3-C_8) -cocloalkyl, (C_3-C_8) -cycloalkyl- (C_4-C_4) -alkyl, optionally substituted (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 89, wherein R⁰ is biphenylylmethyl, naphthylmethyl or benzyl each of which is unsubstituted or monosubstituted or polysubstituted in the aryl radical wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 24, wherein

B is a bivalent radical from he group consisting of methylene, ethylene, trimethylene, tetramethylene, vinylene, phenylene, or is substituted methylene or ethylene;

R is hydrogen, (C_1-C_6) -alkyl or benzyl;

R^o is (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl-aryl-alkyl optionally substituted in the aryl radical;

R¹ is X-NH-C(=NH), X-NH-C(=NX)-NH or X-NH-CH₂;

X is hydrogen, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_8) -alkylcarbonyloxy- (C_1-C_6) -alkoxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl or hydroxyl;

 R^2 is hydrogen or (C_1/C_8) -alkyl;

R³ is (C_1-C_8) -alkyl, optionally substituted (C_6-C_{14}) -aryl, (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, (C_2-C_8) -alkenyl, (C_2-C_8) -alkynyl, pyridyl, R¹¹NH, R⁴CO, COOR⁴, CONHR¹⁴, CSNHR¹⁴, COOR¹⁵ and CONHR¹⁵;

and e, g and h independently of one another are the numbers 0, 1, 2 or 3; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

91. The method as claimed in claim 24, wherein W is R^1 -A-C(R^{13}) and R^{13} is (C_1 - C_6)-alkyl, (C_6 - C_{14})-aryl-(C_1 - C_8)-alkyl optionally substituted in the aryl radical or (C_3 - C_8)-cycloalkyl; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 24, wherein R^3 is optionally substituted (C_6-C_{14}) -aryl, COOR⁴, R^{11} NH or CONHR ⁴, where -NHR¹⁴ is the radical of an α -amino acid, its ω -amino- (C_2-C_8) -alkylamide, its (C_1-C_8) -alkyl ester or its (C_6-C_{14}) -aryl- (C_1-C_4) -alkyl ester; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 93, wherein the radical of the α -amino acid is selected from the group consisting of value, lysine, phenylglycine, phenylalanine, tryptophan, and their (C_1-C_8) -alkyl esters or (C_6-C_{14}) -alkyl esters; wherein said compound or compounds





10/14/88 INC 22.28 FAR 0381

Serial No. 08/971,960

5/107

may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

9 The method as claimed in claim 24, wherein

Z is $N(R^0)$;

A is ethylene, trimethylene, tetramethylene, pentamethylene, cyclohexylene, phenylene or phenylenemethyl;

B is an unsubstituted or substituted methylene radical;

D is $C(R^2)(R^3)$;

R is hydrogen or (C_1-C_4) -alky/

is (C_1-C_8) -alkyl, (C_3-C_8) -cloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl-aryl-aryl-alkyl optionally substituted in the aryl radical;

 R^1 is $H_2N-C(=NH)$, $H_2N/C(=NH)-NH$ or H_2N-CH_2 ;

R² is hydrogen;

R³ is the radical CONIAR¹⁴;

 R^{10} is hydroxyl or (C/C_8) -alkoxy;

 R^{13} is (C_1-C_6) -alkyl, (C_3-C_7) -c; cloalkyl or benzyl;

is methyl which is substituted by hydroxycarbonyl and a radical from the group consisting of $(C_1 - C_4)$ alkyl, phenyl and benzyl, or is methyl which is substituted by $(C_1 - C_8)$ -alkoxycarbonyl and a radical from the group consisting of $(C_1 - C_4)$ -alkyl, phenyl and benzyl;

b, c and d are 1 and e and g are 0

h is 1 or 2; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 24, wherein simultaneously W is R¹-A-C(R¹³) and therein A is a bivalent radical selected from the group consisting of methylene, ethylene, trimethylene, tetramethylene, pentamethylene, cyclohexylene, phenylene, phenylenemethyl;

B is a bivalent radical from the group consisting of methylene, ethylene, trimethylene, tetramethylene, vinylene, phenylene or is substituted methylene or ethylene;

R is hydrogen or (C_1-C_6) -alkyl;

R⁰ is (C_1-C_8) -alkyl, (C_3-C_8) -c/cloa/kyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl-aryl optionally substituted in the aryl radical;

R¹ is X-NH-C(=NH), X-NH- ϕ (=NX)-NH or X-NH-CH₂;

is hydrogen, (C_1-C_6) -alkylcarbonyl, (C_1-C_6) -alkoxycarbonyl, (C_1-C_8) -alkylcarbonyloxy- (C_1-C_6) -alkoxycarbonyl, (C_6-C_{14}) -aryl- (C_1-C_6) -alkoxycarbonyl or hydroxyl;

 R^2 is hydrogen or (C_1-C_8) /alkyl;

R³ is CONHR¹⁵ or CONHR¹⁴ where R¹⁴ herein is a (C_1-C_8) -alkyl radical which is unsubstituted or substituted by one or more (C_6-C_{16}) -aryl radicals;

 R^{15} is R^{16} -(C_1 - C_6)-alkyl or R^{16} where R^{16} is a 7- to 12-membered bridged bicyclic or tricyclic radical which is saturated or partially unsaturated and which can also contain one to four identical or different heteroaloms from the group consisting of nitrogen, oxygen and sulfur and which can also be substituted by one or more identical or different substituents from the group consisting of (C_1-C_4) -allyl and oxo;

and e, g and h independently of one another are the numbers 0, 1, 2 or 3 and b, c and d are 1; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 96, wherein R¹⁵ is an adamantyl radical or an adamantylmethyl radical; wherein said compound or compounds may be present in all their stereoisometric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

97. The method as claimed in claim 24, wherein

A is ethylene, trimethylene, tetramethylene, pentamethylene, cyclohexylene, phenylene or phenylenemethyl;

B is an unsubstituted or substituted methylene radical;

D is $C(R^2)(R^3)$;

R is hydrogen or (C_1-C_4) -alkyl;

R⁰ is (C_1-C_8) - alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl- (C_1-C_8) -alkyl optionally substituted in the aryl radical;

R¹ is $II_2N-C(=NII)$, $II_2N-C(=NH)-NH$ or II_2N-CH_2 ;

R² is hydrogen;

R³ is CONHR¹⁵ or CONHR¹⁴ where R¹⁴ herein is a (C_1-C_6) -alkyl radical which is unsubstituted or substituted by one or more (C_6-C_{10}) -aryl radicals;

 R^{10} is hydroxyl or (C_1-C_1) -alkoxy;

 R^{13} is (C_1-C_6) -alkyl, (C_6-C_7) -cycloalkyl or benzyl;

R¹⁵ is an adamantyl radical or an adamantylmethyl radical;

b, c and d are 1 and e and g are 0;

h is 1 or 2; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 24, wherein

A is ethylene, trimethylene, etramethylene, pentamethylene, cyclohexylene, phenylene, phenylenemethyl;

B is an unsubstituted pr substituted methylene radical or ethylene radical;

D is $C(\mathbb{R}^2)(\mathbb{R}^3)$;

R is hydrogen or (C_1-C_4) -alkyl;

is (C_1-C_8) -alkyl, (C_3-C_8) -ercloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl-aryl-aryl which is optionally substituted in the aryl radical;

R¹ is $H_2N-C(=NH)$, $H_2N-C(:=NH)$ /NH or H_2N-CH_2 ;

R² is hydrogen;

is an unsubstituted phenyl radical or naphthyl radical, a phenyl radical or naphthyl radical substituted by one, two or three identical or different radicals from the group consisting of (C_1-C_4) -alkyl, (C_1-C_4) -alkoxy, hydroxyl, halogen, trifluoromethyl, nitro, methylenedioxy, ethylenedioxy, hydroxycarbonyl, (C_1-C_4) -alkoxycarbonyl, aminocarbonyl, cyano, phenyl, phenoxy, benzyl and benzyloxy, a pyridyl radical, a (C_1-C_4) -alkyl radical, a (C_2-C_4) -alkynyl radical pr a (C_5-C_6) -cycloalkyl radical;

R¹⁰ is hydroxyl or (C₁-C₈)-alk(1)xy;

 R^{13} is (C_1-C_6) -alkyl, (C_3-C_7) -cycloalkyl or benzyl;

b, c and d are 1 and e and g are 0;

h is 1 or 2; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

199. The method as claimed in claim 24, wherein

A is ethylene, trimethylene, retramethylene, pentamethylene, cyclohexylene, phenylene, phenylene, phenylene, phenylene, phenylene, cyclohexylene, phenylene, phenylen

B is an unsubstituted or substituted methylene radical or ethylene radical;

D is $C(\mathbb{R}^2)(\mathbb{R}^3)$;

R is hydrogen or (C_1-C_4) -alkyl;

R⁰ is (C_1-C_8) -alkyl, (C_3-C_8) -cycloalkyl, optionally substituted (C_6-C_{14}) -aryl or (C_6-C_{14}) -aryl or (C_1-C_8) -alkyl, optionally substituted in the aryl radical;

10/14/89 INU 22.20 PAA 0381

19D INTAM

Serial No. 08/971,960

 R^1 is $H_2N-C(=NH)$, $H_2N-C(=NH)$ -NH or H_2N-CH_2 ;

R² is hydrogen;

 R^3 is $R^{11}NH$;

 R^{10} is hydroxyl or (C_1-C_8) -alkoxy;

 R^{13} is (C_1-C_6) -alkyl, (C_3/C_7) -cycloalkyl or benzyl;

b, c, d and e are 1 and g is 0;

h is 0; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

The method as claimed in claim 24 in which a substituted methylene radical or substituted ethylene radical representing the group B carries as a substituent a radical selected from the group consisting of (C_1-C_8) -alkyl, (C_2-C_6) -alkenyl, (C_2-C_6) -alkynyl, (C_3-C_8) -cycloalkyl, (C_3-C_8) -cycloalkyl- (C_3-C_4) -alkyl, optionally substituted (C_6-C_{10}) -aryl, (C_6-C_{10}) -aryl- (C_1-C_4) -alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl and heteroaryl- (C_1-C_4) -alkyl; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.

- 101. The method as claimed in claim 24, in which B is an unsubstituted methylene radical or a methylene radical which is substituted by a (C₁-C₈)-alkyl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts.
- The method as claimed in claim 24, in which B is an unsubstituted methylene radical or a methylene radical v/hich is substituted by a (C_1-C_6) -alkyl radical; wherein said compound or compounds may be present in all their stereoisomeric forms and mixtures thereof in any ratio, and/or as their physiologically tolerable salts. --